



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/54, 9/12, C07K 16/40, A61K 38/17, G01N 33/50</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/66049</b> <b>(43) International Publication Date:</b> 23 December 1999 (23.12.99)
<b>(21) International Application Number:</b> PCT/CA99/00545 <b>(22) International Filing Date:</b> 11 June 1999 (11.06.99)  <b>(30) Priority Data:</b> 60/089,189 12 June 1998 (12.06.98) US 60/096,026 10 August 1998 (10.08.98) US  <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF GUELPH [CA/CA]; Office of the Vice President of Research, Reynolds Building, Room 214, Guelph, Ontario N1G 2W1 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WHITFIELD, Chris [CA/CA]; 21 Springdale Boulevard, Guelph, Ontario N1H 6X5 (CA). YETHON, Jeremy, A. [CA/CA]; 338 Ironwood Road, Guelph, Ontario N1G 3N8 (CA). HEINRICHS, David, E. [CA/CA]; 6 Delaware Street, Guelph, Ontario N1E 3V3 (CA).  <b>(74) Agent:</b> BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> A NOVEL GENE AND METHOD OF TREATING A GRAM NEGATIVE BACTERIAL INFECTION		
<b>(57) Abstract</b>  Described are a novel gene ( <i>waaP</i> ) and a protein (WaaP) which has an enzymatic activity that is involved in heptose modification in the lipopolysaccharide of bacterial membranes. Also described is a method and series of compounds which are active against bacterial pathogens wherein the method comprises the administration of sufficient amount of an inhibitor of WaaP protein activity in gram negative bacteria.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

Title: A Novel Gene and Method of Treating a Gram Negative Bacterial Infection  
FIELD OF THE INVENTION

The invention relates to a novel gene, *waaP*, which is involved in heptose modification in the lipopolysaccharide of bacterial membranes, its corresponding protein, WaaP, and a method of preventing or treating gram negative bacterial infections, particularly attenuating virulent gram negative pathogens including compounds for such attenuation.

BACKGROUND OF THE INVENTION

The outer membrane of Gram-negative bacteria is a barrier to many antibiotics and host defense factors (Vaara, M., 1992). The outer leaflet of this membrane is comprised almost exclusively of lipopolysaccharide (LPS), a unique glycolipid with structural features essential to outer membrane stability. In *Escherichia coli* and *Salmonella enterica*, the LPS molecule is conceptually divided into three distinct regions: 1) a hydrophobic membrane anchor designated lipid A; 2) a short chain of sugar residues with multiple phosphoryl substituents, referred to as the core oligosaccharide (core OS); and 3) a structurally diverse polymer composed of oligosaccharide repeats, termed the O antigen. Lipid A and the core OS are synthesized together as a single unit (lipid A-core, Fig. 1), which serves as an acceptor for preformed O antigen to yield the completed LPS molecule (Whitfield, C. et al., 1997; Raetz, C.R.H. 1996).

Five distinct core OS structures have been identified in *E. coli* (core types K-12, R1, R2, R3, and R4), and two more are known for *S. enterica* (Holst, O. and Brade, H., 1992; Olsthoorn, M.M.A., et al. 1998). The genes responsible for biosynthesis of the core OS in these bacteria are clustered on the chromosome in the *waa* (formerly *rfa*) locus near 81 min on the *E. coli* K-12 and *S. enterica* linkage maps. Mutations in many of the glycosyl transferases encoded by this locus result in the production of LPS lacking O antigen (termed rough- or R-LPS) since O antigen cannot be ligated to an incomplete lipid A-core acceptor molecule. Strains which produce only R-LPS are more susceptible to complement-mediated serum killing than their wild-type counterparts (reviewed in Whitfield, C., 1994). Mutations in the *waa* locus which specifically affect the phosphoryl substitution of the core OS heptose region (Fig. 1) can significantly alter outer membrane permeability, giving rise to a pleiotropic phenotype called 'deep rough' (Helander, I.M. et al., 1989; Nikaido, H. 1996). Characteristics of the deep-rough phenotype include the following: 1) hypersensitivity to detergents and hydrophobic antibiotics, 2) sloughing of LPS from the outer membrane, 3) leakage of periplasmic proteins into the culture medium, and 4) a marked decrease in the protein content of the outer membrane (reviewed in Schnaitman, C.A. et al. 1993). The phosphoryl substituents in the heptose region are postulated to be so critical to outer

membrane stability because their negative charge allows neighbouring LPS molecules to be crosslinked by divalent cations (Vaara, M. 1992; Nikaido, H. and Vaara, M., 1995).

Previous studies with *S. enterica* serovars Minnesota and Typhimurium (Helander, I.M., et al. 1989), and with *E. coli* K-12 (Parker, C.T., et al. 1992) have implicated *waaP* in the phosphorylation of both Heptose I ("HepI") and Heptose II ("HepII") (see Fig. 1). Mutation of *waaP* in these organisms was also reported to cause characteristics of the deep-rough phenotype. Furthermore, in *E. coli* K-12, *waaP* has been implicated in the addition of HepIII (Fig. 1). Interpretation of these data, however, has been complicated by their reliance on strains with poorly-defined or polar mutations.

The R1 core is the most prevalent among clinical isolates of *E. coli* (Gibb, A.P. et al., 1992) and since its structure is known (Jansson, P.-E., et al. 1981) and the genetics of its outer portion have been resolved (Heinrichs, D.E., et al., 1998), studies were performed using the prototype *E. coli* R1 strain, F470. However, three genes in the *waaQ* operon of the *E. coli* R1 *waa* locus (Fig. 2B) have no clearly assigned function: *waaQ*, *P*, and *Y*.

#### SUMMARY OF THE INVENTION

The present inventors have made precise, non-polar insertion mutations in the *waaQ*, *P*, and *Y* genes of *E. coli* F470, and determined that the enzyme encoded by *waaP* is responsible for modification of the heptose ("Hep") in the heptose region ("Hep region") by the phosphoryl substitution of the heptose units of the region. The inventors have also identified and isolated highly conserved homologs of the *waaP* gene from LPS core types R1, R3 and R4 from *E. coli* F470, F653, and F2513, respectively. The inventors have found that the activity of WaaP is to add the phosphoryl substituent to HepI, and that this activity is a prerequisite to the operation of WaaQ and WaaY (both of which are required for the phosphorylation of Hep II). Consequently, the identification and isolation of the *waaP* gene permits the determination of substances which affect modification of the Hep region, and particularly the modification of Hep I. These substances may be useful in attenuating virulent gram negative pathogens in a host infected by such pathogens.

Accordingly, the present invention provides an isolated nucleic acid molecule containing a sequence encoding the enzyme WaaP which is responsible for modification of the Hep region of LPS by the phosphoryl substitution of the Hep units of the region.

The nucleic acid sequence of *waaP* is shown in SEQ.ID.NO.:1 (from F470) or SEQ.ID.NO.:3 (from F653) or SEQ.ID.NO.:5 (from F2513). The corresponding amino acid sequence encoded by each one of these nucleic acid sequences of *waaP* is shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6, respectively.

Accordingly, in one embodiment of the invention, an isolated nucleic acid

molecule is provided having a sequence as shown in SEQ.ID. No.:1 or SEQ.ID.NO.: 3 or SEQ.ID.NO.:5.

Preferably, the purified and isolated nucleic acid molecule comprises

(a) a nucleic acid sequence as shown in SEQ. ID. NO.: 1 or SEQ.ID.NO.:3 or  
5 SEQ.ID.NO.:5, wherein T can also be U;

(b) nucleic acid sequences complementary to (a);

(c) nucleic acid sequences which are homologous to (a) or (b);

(d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases,  
and which will hybridize to (a) to (d) under stringent hybridization conditions; or

10 (e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in  
codon sequences due to the degeneracy of the genetic code.

The invention further includes an isolated protein encoded by a nucleic acid  
molecule of the invention. Accordingly a preferred embodiment has the amino acid as  
shown in SEQ. ID. NO. 2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6.

15 The invention further provides a method of preventing or treating a gram  
negative bacterial infection comprising administering an effective amount of a  
substance that inhibits WaaP to an animal in need thereof.

According to one embodiment, there is provided a method for attenuating  
virulent gram negative pathogens comprising administering a sufficient amount of an  
20 inhibitor of WaaP to attenuate the pathogen. Preferably, the gram negative  
pathogen is selected from the group of pathogens including *Salmonella enterica*,  
*Escherichia coli*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Shigella flexneri*, *Shigella*  
*dysenteriae*, and *Pseudomonas aeruginosa* serotypes 02, 05, 16, 18 and 20, *P. aeruginosa*  
serotypes 03 or 06 and other members of the family Pseudomonadaceae.

25 Inhibitors of the invention include antibodies which inhibit the activity of  
the WaaP protein; antibodies which inhibit interaction of the WaaP substrate with  
the WaaP protein; and antisense oligonucleotide which inhibit translation of the  
*waaP* gene.

According to another embodiment, the present invention provides a method of  
30 assaying for inhibitors of WaaP, under appropriate conditions, comprising the steps of  
incubating a gram negative pathogen with a test substance which is suspected of  
affecting WaaP activity and determining the effect of the substance, preferably  
phosphorylation of Hep, by comparing to a control. Accordingly, using the methods of  
the present invention, inhibitors of WaaP in gram negative pathogens will be  
35 identified.

According to a further embodiment of the present invention, there is provided  
a method of treating or preventing a gram negative bacterial infection comprising  
administering an effective amount of a composition that inhibits WaaP activity,  
preferably in an animal in need thereof, wherein the composition comprises

inhibitors of WaaP activity, preferably in a pharmaceutically acceptable diluent or carrier.

In another embodiment, the present invention provides a vaccine for preventing or treating a gram negative bacterial infection, preferably in an animal in need thereof, comprising an effective amount of a WaaP protein in admixture with a suitable diluent or carrier.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in relation to the drawings in which:

Figure 1 shows a generalized structure of a lipid A-core portion of a lipopolysaccharide common to *E. coli* and *S. enterica*, highlighting the heptose region.

Figure 2 shows the structure of the R1 core OS of *E. coli* F470, and the genetic organization of the *waa* locus indicating the locations of the non-polar insertion mutations.

Figure 3 illustrates the methylation linkage analyses and  $^{31}\text{P}$ -NMR spectroscopy of the core OSs from F470 and derivatives.

Figure 4 shows the nucleic acid sequence of *waaP* from *E. coli* F470, representative of the R1 LPS core type (SEQ. I.D. No. 1).

Figure 5 shows the deduced amino acid sequence from the nucleic acid sequence of Figure 4 for the WaaP protein of F470 (SEQ. I.D. No. 2).

Figure 6 shows the nucleic acid sequence of *waaP* from *E. coli* F653, representative of the R3 LPS core type (SEQ. I.D. No. 3).

Figure 7 shows the deduced amino acid sequence from the nucleic acid sequence of Figure 6 for the WaaP protein of F653 (SEQ. I.D. No. 4).

Figure 8 shows the nucleic acid sequence of the *waaP* from *E. coli* F2513, representative of the R4 LPS core type (SEQ. I.D. No. 5).

Figure 9 shows the deduced amino acid sequence from the nucleic acid sequence of Figure 8 for the WaaP protein of F2513 (SEQ. I.D. No. 6).

#### DETAILED DESCRIPTION OF THE INVENTION

As mentioned above, the inventors have isolated and characterized the gene (*waaP*) and its gene product (WaaP) from LPS core types R1, R3 and R4 from *E. coli* F470, F653, and F2513, respectively.

As used in this specification, the term "effective amount" means an amount

effective and at dosages and for periods of time necessary to achieve the desired result.

The term "animal" as used herein includes all members of the animal kingdom including mammals, preferably humans.

## 5 I. NUCLEIC ACID MOLECULES OF THE INVENTION

The term "isolated" refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. The term "nucleic acid" is intended to include DNA and RNA and can be either double stranded  
10 or single stranded.

Broadly stated, the present invention provides an isolated nucleic acid molecule containing a sequence encoding an active protein with the enzyme activity of WaaP. In an embodiment of the invention, an isolated nucleic acid molecule is provided having a sequence as shown in SEQ.ID. No.: 1 or SEQ.ID.NO.:3 or  
15 SEQ.ID.NO.:5.

Preferably, the purified and isolated nucleic acid molecule comprises:

(a) a nucleic acid sequence as shown in SEQ. ID. NO.: 1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5, wherein T can also be U;

(b) nucleic acid sequences complementary to (a);

20 (c) nucleic acid sequences which are homologous to (a) or (b);

(d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases, and which will hybridize to (a) to (c) under stringent hybridization conditions; or

(e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.

25 It will be appreciated that the invention includes nucleic acid molecules encoding truncations of the proteins of the invention, and analogs and homologs of the proteins of the invention and truncations thereof, as described below. It will further be appreciated that variant forms of the nucleic acid molecules of the invention which arise by alternative splicing of an mRNA corresponding to a cDNA of the invention are  
30 encompassed by the invention.

Further, it will be appreciated that the invention includes nucleic acid molecules comprising nucleic acid sequences having substantial sequence homology with the nucleic acid sequences as shown in SEQ. ID. NO.: 1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5 and fragments thereof. The term "sequences having substantial sequence  
35 homology" means those nucleic acid sequences which have slight or inconsequential sequence variations from these sequences, i.e., the sequences function in substantially the same manner to produce functionally equivalent proteins. The variations may be attributable to local mutations or structural modifications.

Generally, nucleic acid sequences having substantial homology include nucleic

acid sequences having at least 70%, preferably 80-90% identity with the nucleic acid sequence as shown in SEQ. ID. NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5.

Another aspect of the invention provides a nucleic acid molecule, and fragments thereof having at least 15 bases, which hybridize to the nucleic acid molecules of the invention under hybridization conditions, preferably stringent hybridization conditions. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or may be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the following may be employed: 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C. The stringency may be selected based on the conditions used in the wash step. For example, the salt concentration in the wash step can be selected from a high stringency of about 2.0 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Isolated and purified nucleic acid molecules having sequences which differ from the nucleic acid sequence shown in SEQ.ID.NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5 due to degeneracy in the genetic code are also within the scope of the invention.

Nucleic acid molecules from *waaP* gene can be isolated by preparing a labelled nucleic acid probe based on all or part of the nucleic acid sequence as shown in SEQ.ID.NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5, and using this labelled nucleic acid probe to screen an appropriate DNA library (e.g. a cDNA or genomic DNA library). Nucleic acids isolated by screening of a cDNA or genomic DNA library can be sequenced by standard techniques.

Nucleic acid molecules of the invention can also be isolated by selectively amplifying a nucleic acid using the polymerase chain reaction (PCR) method and cDNA or genomic DNA. It is possible to design synthetic oligonucleotide primers from the nucleic acid molecule as shown in SEQ.ID.NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5 for use in PCR. A nucleic acid can be amplified from cDNA or genomic DNA using these oligonucleotide primers and standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. It will be appreciated that cDNA may be prepared from mRNA, by isolating total cellular mRNA by a variety of techniques, for example, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al., Biochemistry, 18, 5294-5299 (1979). cDNA is then synthesized from the mRNA using reverse transcriptase (for example, Moloney MLV reverse transcriptase available from Gibco/BRL, Bethesda, MD, or AMV reverse transcriptase available from Seikagaku America, Inc., St. Petersburg, FL).

An isolated nucleic acid molecule of the invention which is RNA can be

isolated by cloning a cDNA encoding a novel protein of the invention into an appropriate vector which allows for transcription of the cDNA to produce an RNA molecule which encodes the WaaP protein. For example, a cDNA can be cloned downstream of a bacteriophage promoter, (e.g., a T7 promoter) in a vector, cDNA can be transcribed *in vitro* with T7 polymerase, and the resultant RNA can be isolated by standard techniques.

A nucleic acid molecule of the invention may also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071).

The initiation codon and untranslated sequences of the nucleic acid molecules of the invention may be determined using currently available computer software designed for the purpose, such as PC/Gene (IntelliGenetics Inc., Calif.). Regulatory elements can be identified using conventional techniques. The function of the elements can be confirmed by using these elements to express a reporter gene which is operatively linked to the elements. These constructs may be introduced into cultured cells using standard procedures. In addition to identifying regulatory elements in DNA, such constructs may also be used to identify proteins interacting with the elements, using techniques known in the art.

The invention also provides nucleic acids encoding fusion proteins comprising a novel protein of the invention and a selected protein, or a selectable marker protein (see below).

#### Antisense molecules

Antisense oligonucleotides that are complimentary to a nucleic acid sequence from any one of the *waaP* genes described herein can also be used in the methods of the present invention to inhibit WaaP activity.

Accordingly, the present invention provides a method of preventing or treating a gram negative bacterial infection comprising administering an effective amount of an antisense oligonucleotide that is complimentary to a nucleic acid sequence from a *waaP* gene to an animal in need thereof.

Plasmid pWQ909 contains the *waaP* gene and may be used to develop antisense molecules as described below and to provide protein for the methods and assays described herein.

The term "antisense oligonucleotide" as used herein means a nucleotide sequence that is complimentary to its target.

The term "oligonucleotide" refers to an oligomer or polymer of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars, and intersugar

(backbone) linkages. The term also includes modified or substituted oligomers comprising non-naturally occurring monomers or portions thereof, which function similarly. Such modified or substituted oligonucleotides may be preferred over naturally occurring forms because of properties such as enhanced cellular uptake, or increased stability in the presence of nucleases. The term also includes chimeric oligonucleotides which contain two or more chemically distinct regions. For example, chimeric oligonucleotides may contain at least one region of modified nucleotides that confer beneficial properties (e.g. increased nuclease resistance, increased uptake into cells), or two or more oligonucleotides of the invention may be joined to form a chimeric oligonucleotide.

The antisense oligonucleotides of the present invention may be ribonucleic or deoxyribonucleic acids and may contain naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The oligonucleotides may also contain modified bases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-aminoadenine, 8-thiol adenine, 8-thiolalkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thiolalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

Other antisense oligonucleotides of the invention may contain modified phosphorous, oxygen heteroatoms in the phosphate backbone, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. For example, the antisense oligonucleotides may contain phosphorothioates, phosphotriesters, methyl phosphonates, and phosphorodithioates. In an embodiment of the invention there are phosphorothioate bonds links between the four to six 3'-terminus bases. In another embodiment phosphorothioate bonds link all the nucleotides.

The antisense oligonucleotides of the invention may also comprise nucleotide analogs that may be better suited as therapeutic or experimental reagents. An example of an oligonucleotide analogue is a peptide nucleic acid (PNA) wherein the deoxyribose (or ribose) phosphate backbone in the DNA (or RNA), is replaced with a polyamide backbone which is similar to that found in peptides (P.E. Nielsen, et al Science 1991, 254, 1497). PNA analogues have been shown to be resistant to degradation by enzymes and to have extended lives *in vivo* and *in vitro*. PNAs also bind stronger to a complimentary DNA sequence due to the lack of charge repulsion between the PNA strand and the DNA strand. Other oligonucleotides may contain nucleotides containing polymer backbones, cyclic backbones, or acyclic backbones. For

example, the nucleotides may have morpholino backbone structures (U.S. Pat. No. 5,034, 506). Oligonucleotides may also contain groups such as reporter groups, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an antisense oligonucleotide. Antisense oligonucleotides may also have sugar mimetics.

The antisense nucleic acid molecules may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. The antisense nucleic acid molecules of the invention or a fragment thereof, may be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed with mRNA or the native gene (e.g. phosphorothioate derivatives and acridine substituted nucleotides). The antisense sequences may be produced biologically using an expression vector introduced into cells in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense sequences are produced under the control of a high efficiency regulatory region, the activity of which may be determined by the cell type into which the vector is introduced.

The antisense oligonucleotides may be introduced into tissues or cells using techniques in the art including vectors (retroviral vectors, adenoviral vectors and DNA virus vectors) or physical techniques such as microinjection. The antisense oligonucleotides may be directly administered *in vivo* or may be used to transfect cells *in vitro* which are then administered *in vivo*. In one embodiment, the antisense oligonucleotide may be delivered to macrophages and/or endothelial cells in a liposome formulation.

## 25 II. NOVEL PROTEINS OF THE INVENTION

The invention further includes an isolated protein encoded by nucleic acid molecules of the invention. Within the context of the present invention, a protein of the invention may include various structural forms of the primary protein which retain biological activity.

30 The term "WaaP" or "WaaP protein" as used herein is intended to include analogs of WaaP, containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made the resulting analog should be functionally equivalent to WaaP. Non-conserved substitutions involve replacing one or more amino acids with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into the amino acid

sequence of WaaP. Amino acid insertions may consist of single amino acid residues or sequential amino acids.

Deletions may consist of the removal of one or more amino acids, or discrete portions (e.g. amino acids) from the WaaP amino acid sequence. The deleted amino acids may or may not be contiguous.

Also included in the expression "WaaP" or "WaaP protein" as used herein are homologs of WaaP. Such homologs are proteins whose amino acid sequences are comprised of the amino acid sequences of WaaP regions from other sources that hybridize under stringent hybridization conditions (which conditions are known to those skilled in the art) with a probe used to obtain WaaP. It is anticipated that a protein comprising an amino acid sequence which is at least 72% preferably 75 to 90% similar, with the amino acid sequence of WaaP will exhibit WaaP activity.

As used herein the expression "WaaP" or "WaaP protein" also contemplates isoforms of the WaaP protein. An isoform contains the same number and kinds of amino acids as WaaP, but the isoform has a different molecular structure. The isoforms contemplated by the present invention are those having the same properties as the protein of the invention as described herein. Also included in the expression are other enzymes that carry out modifications at other positions of Hep and which share similarities to WaaP, such as, for example the WaaY protein.

Broadly stated, the present invention provides an isolated protein with activity equivalent to that of the WaaP protein. As discussed below, WaaP functions like a kinase, and shares similarities with a large number of kinases.

In preferred embodiments of the invention, the protein has the amino acid sequence as shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6.

In addition to full length amino acid sequences, the proteins of the present invention also include truncations of the protein and analogs and homologs of the protein and truncations thereof as described herein. Truncated proteins may comprise peptides of at least fifteen amino acid residues.

Analogous of the protein having the amino acid sequence shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6 and/or truncations thereof as described herein, may include, but are not limited to, an amino acid sequence containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids of the proteins of the invention with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made the resulting analog should be functionally equivalent. Non-conserved substitutions involve replacing one or more amino acids of the amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into the amino acid sequences shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6. Amino acid insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length. For example, amino acid insertions may be used to destroy target sequences so that the protein is no longer active. This procedure may be used *in vivo* to inhibit the activity of a protein of the invention.

Deletions may consist of the removal of one or more amino acids, or discrete portions from the amino acid sequence shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6. The deleted amino acids may or may not be contiguous. The lower limit length of the resulting analog with a deletion mutation is about 10 amino acids, preferably 100 amino acids.

Analog of a protein of the invention may be prepared by introducing mutations in the nucleotide sequence encoding the protein. Mutations in nucleotide sequences constructed for expression of analogs of a protein of the invention must preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, which could adversely affect translation of the receptor mRNA.

Mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site specific mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Deletion or truncation of a protein of the invention may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989).

The proteins of the invention also include homologs of the amino acid sequence shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6 and/or truncations thereof as described herein. Such homologs are proteins whose amino acid sequences are comprised of amino acid sequences that hybridize under stringent hybridization conditions (see discussion of stringent hybridization conditions herein) with a probe used to obtain a protein of the invention. Preferably, homologs of a protein of the invention will have domains containing motifs shared with various kinases, which is characteristic of the protein.

A homologous protein includes a protein with an amino acid sequence having at least 70%, preferably 80-90% identity with the amino acid sequence as shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6.

5 The invention also contemplates isoforms of the proteins of the invention. An isoform contains the same number and kinds of amino acids as a protein of the invention, but the isoform has a different molecular structure. The isoforms contemplated by the present invention are those having the same properties as a protein of the invention as described herein.

10 The present invention also includes a protein of the invention conjugated with a selected protein, or a selectable marker protein (see below) to produce fusion proteins. Additionally, immunogenic portions of a protein of the invention are within the scope of the invention.

15 The proteins of the invention (including truncations, analogs, etc.) may be prepared using recombinant DNA methods. Accordingly, the nucleic acid molecules of the present invention having a sequence which encodes a protein of the invention may be incorporated in a known manner into an appropriate expression vector which ensures good expression of the protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the vector is compatible with  
20 the host cell used. The expression vectors are "suitable for transformation of a host cell", means that the expression vectors contain a nucleic acid molecule of the invention and regulatory sequences selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid molecule. Operatively linked is intended to mean that the nucleic acid is linked to regulatory sequences in a  
25 manner which allows expression of the nucleic acid.

The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted nucleotide-sequence. Suitable regulatory sequences may be derived from a  
30 variety of sources, including bacterial, fungal, or viral genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990)). Selection of appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such regulatory  
35 sequences include the following: a transcriptional promoter and enhancer or RNA polymerase binding sequence, or a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may

be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences may be supplied by the native gene and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a  
5 DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to a nucleotide sequence comprising the nucleotides as shown SEQ.ID.NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5.  
10 Regulatory sequences operatively linked to the antisense nucleic acid can be chosen which direct the continuous expression of the antisense RNA molecule.

The recombinant expression vectors of the invention may also contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of selectable  
15 marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs,  $\beta$ -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as  $\beta$ -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene  
20 encodes a protein conferring antibiotic resistance such as neomycin resistance transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors of the invention and in particular to determine the effect of a mutation on expression and phenotype. It  
25 will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.

The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aids in the purification of a target  
30 recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.

Recombinant expression vectors can be introduced into host cells to produce a  
35 transformant host cell. The term "transformant host cell" is intended to include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques

known in the art. Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated  
5 transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host  
10 cells. For example, the proteins of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

The proteins of the invention may also be prepared by chemical synthesis  
15 using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

### III. METHODS OF PREVENTING A GRAM NEGATIVE BACTERIAL INFECTION

20 As mentioned above, the invention provides a method of preventing or treating a gram negative bacterial infection comprising administering an effective amount of a substance that inhibits WaaP to an animal in need thereof.

The gram negative bacteria may be any bacteria that expresses WaaP including *Salmonella enterica*, *Escherichia coli*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Shigella flexneri*, *Shigella dysenteriae*, *Pseudomonas aeruginosa*  
25 serotypes 02, 05, 16, 18 and 20, *P. aeruginosa* serotypes 03 or 06 and other members of the family Pseudomonadaceae.

The present inventors have made precise, non-polar insertion mutations in the *waaQ*, *P*, and *Y* genes of *E. coli* F470, and determined that the enzyme encoded by *waaP*  
30 is responsible for the phosphorylation of Hep of the Hep region. In particular, it has been found that Hep III is transferred to the Hep region by WaaQ activity and that this is required for phosphorylation of Hep II. Hep II phosphorylation is catalyzed by WaaY. Further, it has been found that Hep I phosphorylation is brought about by WaaP, and that this activity is a prerequisite for the operation of WaaQ and WaaY,  
35 and that mutation of *waaP* such that WaaP activity is antagonized results in no phosphorylation of Hep.

Thus, according to one embodiment the invention provides substances for attenuating a virulent gram negative pathogen, preferably inhibitors of WaaP activity, and preferably in an animal in need thereof.

According to another embodiment the invention provides a method of attenuating a virulent gram negative pathogen comprising administering a sufficient amount of an inhibitor of WaaP activity to attenuate the pathogen, preferably in an animal in need thereof, preferably in gram negative bacteria, more preferably in

5 *Salmonella enterica* *Escherichia coli*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Shigella flexneri*, *Shigella dysenteriae*, *Pseudomonas aeruginosa* serotypes 02, 05, 16, 18 and 20, *P. aeruginosa* serotypes 03 or 06 and other members of the family Pseudomonadaceae.

Substances that inhibit the activity of the WaaP protein may be substances

10 that interfere with the WaaP protein (such as antibodies or other protein ligands) or substances that interfere with the expression of the *waaP* gene such as antisense molecules.

#### Antibodies

A WaaP protein can be used to prepare antibodies specific for the enzyme.

15 Antibodies can be prepared which bind a distinct epitope in an unconserved region of the protein. An unconserved region of the protein is one which does not have substantial sequence homology to other proteins. Alternatively, a region from a well-characterized domain can be used to prepare an antibody to a conserved region of the WaaP protein. Antibodies having specificity for WaaP may also be raised from

20 fusion proteins.

Conventional methods can be used to prepare antibodies. For example, by using WaaP protein, polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g. a mouse, hamster, or rabbit) can be immunized with an immunogenic form of the polypeptide which elicits an antibody response in

25 the mammal. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art. For example, the peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the

30 levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.

To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma

35 cells. Such techniques are well known in the art, (e.g. the hybridoma technique originally developed by Kohler and Milstein (Nature 256, 495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4, 72 (1983)), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. Monoclonal Antibodies in Cancer Therapy (1985)

Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., Science 246, 1275 (1989)). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the WaaP peptide and the monoclonal antibodies can be isolated. Therefore, the invention also  
5 contemplates hybridoma cells secreting monoclonal antibodies with specificity for WaaP protein.

The term "antibody" as used herein is intended to include fragments thereof which also specifically react with WaaP protein. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as  
10 described above. For example, F(ab')<sub>2</sub> fragments can be generated by treating antibody with pepsin. The resulting F(ab')<sub>2</sub> fragment can be treated to reduce disulfide bridges to produce Fab' fragments.

Chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region are also contemplated  
15 within the scope of the invention. Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions. Conventional methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes the gene product of the genes of the *psb* cluster of the invention (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452  
20 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom patent GB 2177096B).

Monoclonal or chimeric antibodies specifically reactive with WaaP protein  
25 can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such immunoglobulin molecules may be made by techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4, 7279 (1983); Olsson et al., Meth. Enzymol., 92, 3-16  
30 (1982)), and PCT Publication WO92/06193 or EP 0239400). Humanized antibodies can also be commercially produced (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.)

Specific antibodies, or antibody fragments, reactive against WaaP protein  
35 may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with peptides produced from the nucleic acid molecules of the present invention. For example, complete Fab fragments, VH regions and FV regions can be expressed in bacteria using phage expression libraries (See for example Ward et al., Nature 341, 544-546: (1989); Huse et al., Science 246, 1275-1281

(1989); and McCafferty et al. Nature 348, 552-554 (1990)). In an embodiment of the invention, antibodies that bind to an epitope of a protein of the invention are engineered using the procedures described in N. Tout and J. Lam (Clin. Diagn. Lab. Immunol. Vol. 4(2):147-155, 1997).

5       The antibodies may be labelled with a detectable marker including various enzymes, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, biotin, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable  
10       fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable  
15       radioactive material include S-35, Cu-64, Ga-67, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I131, Re-186, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. The antibodies may also be labelled or conjugated to one partner of a ligand binding  
20       pair. Representative examples include avidin-biotin and riboflavin-riboflavin binding protein. Methods for conjugating or labelling the antibodies discussed above with the representative labels set forth above may be readily accomplished using  
25       conventional techniques.

      The antibodies reactive against WaaP protein may be used to detect a protein  
20       of the invention in various samples, for example they may be used in any known immunoassays which rely on the binding interaction between an antigenic determinant of a WaaP protein and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests.

#### 25       Screening for WaaP Inhibitors

      According to an embodiment, of the present invention there is provided a method of assaying for inhibitors of WaaP activity in gram negative pathogens under appropriate conditions comprising the steps of incubating a gram negative pathogen with a test substance which is suspected of affecting WaaP activity and determining  
30       the effect of the substance by comparing to a control. WaaP functions like a kinase and accordingly assays for inhibition of kinase activity are within the scope of the present invention. In respect of WaaP, for example, as will be readily understood by those skilled in the art, WaaP can be expressed in a form which may be rapidly purified (such as a His-tagged construct with 6 histidine residues at its N-terminus) using any  
35       one of a number of chromatographic methods known to those skilled, such as, for example, metal chelate chromatography in open column or High Performance Liquid Chromatography (HPLC) formats. A purified LPS containing lipid A attached to a phosphate-deficient core oligosaccharide as the acceptor molecule can be extracted from a prototype *E. coli waaP* mutant strain(which has a phosphate-deficient core

oligosaccharide) such as , for example strain CWG296. This purification can be conducted by conventional methods. A radio-labelled phosphate of ATP (eg.  $^{31}\text{P}$ -labelled ATP) may be used to provide a phosphodonor in a reaction containing purified WaaP enzyme. Quantification of incorporation of phosphate may be carried out by routine methods such as by separating the LPS from substrate over gel-filtration columns, or by visualization of radiolabel incorporation by separating radiolabeled LPS in sodium dodecyl sulfate gels and exposing the gel to X-ray film. In addition, as is apparent to those skilled in the art, as discussed above under "antibodies", antibodies may be developed which are specific for the phosphorylated heptose that is formed by WaaP thereby allowing for direct detection of enzyme activity in any conventional ELISA format.] As will be appreciated, using the methods of the present invention, inhibitors of WaaP activity in gram negative pathogens will be identified. Accordingly, all inhibitors of WaaP activity in gram negative pathogens are within the scope of the present invention.

#### 15 Compositions

The substances identified by the methods described herein, including antisense nucleic acid molecules, and antibodies, may be used for modulating WaaP protein synthesis and activity and accordingly may be used in the treatment of infections caused by gram negative pathogens. The substances identified by the methods described herein, including antisense nucleic acid molecules, and antibodies are preferably used to treat infections caused by bacteria including *Salmonella enterica*, *Escherichia coli*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Shigella flexneri*, *Shigella dysenteriae*, and *Pseudomonas aeruginosa* serotypes 02, 05, 16, 18 and 20. The substances etc. are also preferably used to treat infections caused by *P. aeruginosa* serotypes 03 or 06 which are predominant clinical isolates. It will be appreciated that the substances may also be useful to treat infections caused by other members of the family Pseudomonadaceae (eg. *Burkholderia cepacia* and *Burkholderia pseudomallei*).

The substances identified using the methods described herein, including antisense nucleic acid molecules, and antibodies, may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals. Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount

of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose  
5 may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of  
10 administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

The compositions described herein can be prepared by *per se* known methods for the preparation of pharmaceutically acceptable compositions which can be  
15 administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the substances in  
20 association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The utility of the substances, antibodies, and compositions of the invention may be confirmed in experimental model systems.

#### 25 Vaccines

The present invention further includes a vaccine for preventing or treating a gram negative bacterial infection comprising an effective amount of a WaaP protein, preferably in admixture with a suitable diluent or carrier.

Accordingly, the present invention also includes a method of preventing or  
30 treating a gram negative bacterial infection comprising administering a vaccine containing an effective amount of a WaaP protein, preferably in admixture with a suitable diluent or carrier, to an animal in need thereof.

The vaccine may include a carrier strain containing a WaaP protein associated with its surface which is effective to provide protection against the bacteria. The  
35 carrier strain may selected so that it is incapable of multiplying *in vivo*. Carrier strains are obtained through selection of variants which occur naturally, or using conventional means known to those skilled in the art. Examples of suitable carrier strains are *Shigella* species, *Salmonella* species, *S.typhimurium*, *Vibrio* species, and *Escherichia* species.

The vaccine may be a multivalent vaccine and additionally contain immunogens related to other infectious diseases in a prophylactically or therapeutically effective manner. Multivalent vaccines against infectious diseases caused by different infectious agents may contain a carrier strain having amounts of  
5 antigens associated with their surfaces which are effective to provide protection against the infectious agents.

The vaccines of the present invention may additionally contain suitable diluents, adjuvants and/or carriers. Preferably, the vaccines contain an adjuvant which can enhance the immunogenicity of the vaccine *in vivo*. The adjuvant may be  
10 selected from many known adjuvants in the art including the lipid-A portion of the LPS from gram negative bacteria (endotoxin), trehalose dimycolate of mycobacteria, the phospholipid lysolecithin, dimethyldioctadecyl ammonium bromide (DDA), certain linear polyoxypropylene-polyoxyethylene (POP-POE) block polymers, aluminum hydroxide, and liposomes. The vaccines may also include cytokines that are  
15 known to enhance the immune response including GM-CSF, IL-2, IL-12, TNF and IFN $\gamma$ . The vaccine may also contain preservatives such as sodium azide, thimersol, beta propiolactone, and binary ethyleneimine.

The vaccine compositions of the invention are suitable for administration to subjects in a biologically compatible form *in vivo*. The expression "biologically  
20 compatible form suitable for administration in vivo" as used herein is means a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to animals, including mammals, avian species, and fish; preferably humans and various other mammals, including bovines, equines, and swine.

The dose of the vaccine may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the  
30 therapeutic situation. The dose of the vaccine may also be varied to provide optimum preventative dose response depending upon the circumstances.

The vaccines may be administered in a convenient manner such as by injection (subcutaneous, intravenous, intramuscular, etc.), oral administration, inhalation, transdermal administration (such as topical cream or ointment, etc.), or suppository  
35 applications.

A vaccine of the invention may contain a nucleic acid molecule encoding a WaaP protein of the invention. In such an embodiment, the WaaP protein is produced *in vivo* in the host animal. The vaccines containing nucleic acids may be delivered using a suitable vector including retroviral vectors, adenoviral vectors and DNA virus

vectors.

A vaccine prepared using the methods described herein may be tested in animal systems *in vivo* to confirm their efficacy in the prophylaxis or active immunization and treatment of infectious diseases caused by gram negative bacteria and to determine appropriate dosages and routes of administration.

As discussed above, WaaP proteins of the invention are also useful for preparing antibodies which may be used as a means of passive immunization.

The following non-limiting examples are illustrative of the present invention:

#### EXAMPLES

##### GENERAL EXPERIMENTAL PROCEDURES AS USED IN THE EXAMPLES

*Bacterial Strains and Growth Conditions* - *E. coli* F470 is an R-LPS derivative of an O8:K27 strain (Schmidt, G. et al, 1969) , and serves as the prototype for R1 core OS studies. Derivatives of F470 used in this study include CWG296 (F470 with a *waaP::aacC1* insertion), CWG297 (F470 with a *waaQ::aacC1* insertion), and CWG312 (F470 with a *waaY::aacC1* insertion). Bacteria were grown in Luria-Bertani (LB) broth at 37°C. Growth media were supplemented with ampicillin (100 µg/mL), gentamicin (15 µg/mL), or chloramphenicol (30 µg/mL) when necessary.

*In vitro Mutagenesis and Gene Replacement* - The *waaY*, *Q*, and *P* genes of the R1 core OS biosynthesis region were independently mutated by insertion of a non-polar gentamicin-resistance cassette (the *aacC1* gene from Tn1696). Briefly, each of the genes (with some flanking DNA) was individually PCR-amplified, cloned into the pBluescript® II SK(+) phagemid (Stratagene), and sequenced to ensure error-free amplification. The *aacC1* gene from plasmid pUCGM (Schweizer, H.P., 1993) was then inserted into an appropriate site (near the middle) of the coding region of each gene (Fig. 2B). The DNA fragment containing the insertionally-inactivated gene was subsequently cloned into the suicide delivery vector pMAK705 (Hamilton, C.A. et al., 1989), and chromosomal gene replacement was performed as described previously (Amor, P.A. and Whitfield, C., 1997). Mutations were verified by PCR amplification of the mutated gene from the chromosome and confirmed by sequencing.

*DNA methods* - Restriction endonuclease digestion and ligation were performed as described by Sambrook *et al.* (Sambrook, J. et al., 1989). Restriction enzymes were purchased from either Life Technologies, Inc. (Burlington, Ontario), New England Biolabs (Mississauga, Ontario), or Boehringer Mannheim (Laval, Quebec). Plasmids were introduced into *E. coli* strains by electroporation using a Gene Pulser from Bio-Rad (Mississauga, Ontario). Chromosomal DNA isolation was performed using the Qiagen genomic DNA isolation kit, and plasmid DNA was prepared using QIAprep Miniprep Spin Columns (Qiagen Inc., Santa Clarita, CA). When necessary, DNA fragments were isolated from agarose gels using the GENECLAN® kit from Bio/Can Scientific

(Mississauga, Ontario).

*PCR and Sequencing Techniques* - Oligonucleotides were synthesized using a Perkin-Elmer 394 DNA synthesizer, and sequencing was performed using an ABI 377 DNA sequencing apparatus (Perkin-Elmer, Norwalk, CT) in the Guelph Molecular  
5 Supercentre at the University of Guelph. PCR amplification was performed using a GeneAmp PCR System 2400 from Perkin-Elmer. The *Pwo*I DNA polymerase enzyme (Boehringer Mannheim) was used as recommended by the manufacturer.

*Cloning and Expression of waaP for Complementation* - Oligonucleotide primers for the amplification of *waaP* from the F470 chromosome were designed to introduce  
10 appropriate restriction sites for cloning. The forward primer (5'-TGTGGATccAAATAGTGGGCACTCA-3')(SEQ. I.D. No. 7) introduced a *Bam*HI site (underlined) 32 base pairs downstream of the *waaP* stop codon, and the complementary reverse primer (5'-GGGTGGTCcatATGTTGAAGTTAA-3')(SEQ. I.D. No. 8) introduced an *Nde*I site (underlined) overlapping the *waaP* start codon (bases shown in  
15 lower case indicate mismatches between the primer and chromosomal sequences). The coding region for *waaP* alone was subsequently isolated as a *Bam*HI-*Nde*I fragment, and cloned behind the arabinose-inducible  $P_{BAD}$  promoter of the expression vector pBAD18, to generate plasmid pWQ909. L-arabinose was used at a final concentration of 0.002% to induce expression of WaaP from plasmid pWQ909.

20 *Computer analyses* - Homology searches of nucleotide and amino acid sequences in the National Center for Biotechnology Information databases were performed using the BLAST (basic local alignment search tool) or PSI (position-specific iterated)-BLAST server analysis programs (Altschul, S.F. et al., 1990; Altschul, S.F. et al., 1997). Pairwise nucleotide sequence alignments and percent identity scores were obtained  
25 using the NALIGN program of the PC/GENE® software package (IntelliGenetics, Inc., Mountain View, CA) with an open gap cost of 25 and a unit gap cost of 5. Multiple protein alignments and percentage identity and similarity scores were obtained using the PC/GENE® program CLUSTALV, with an open gap cost of 10 and a unit gap cost of 10. Routine DNA and protein sequence manipulations were performed using the  
30 MacVector™ and AssemblyLIGN™ software packages (International Biotechnologies, Inc., New Haven, CT).

*Sodium dodecyl sulfate (SDS) and Novobiocin Sensitivity Testing* - Two-fold serial dilutions of SDS (200 → 0.1 mg/mL) and novobiocin (200 → 1.6 µg/mL) were made in 5 mL volumes of LB. Each series of tubes was point inoculated from an overnight culture  
35 of the strain to be tested, and then incubated with shaking at 37°C. Growth was scored as positive if after 8 hours the culture was visibly turbid (i.e.  $A_{600} > 0.2$ ).

*Preparation of Core OSs* - Water-soluble LPSs were obtained by the hot phenol/water extraction of cells (Westphal, O. and Jann, K., 1965), and then treated with 2% acetic

acid at 100°C to cleave the acid-labile ketosidic linkage between the core OS and lipid A. The water-insoluble lipid A was removed by centrifugation (5000 X g, 30 min), and the supernatant was passed through a column of BioGel P-2 (1 m X 1 cm) with water as eluent. The core-containing fractions were collected and lyophilized.

- 5 *Sugar Composition and Methylation Linkage Analyses* - Sugar composition analysis was performed by the alditol acetate method (Sawardeker, J.H. et al., 1967). Hydrolysis of glycosidic bonds was achieved with 4 M trifluoroacetic acid at 100°C for 4 h. The samples were then reduced in water with sodium borodeuteride, and acetylated with acetic anhydride using residual sodium acetate as the catalyst.
- 10 Characterization of the alditol acetate derivatives was performed by gas-liquid chromatography (GLC)-mass spectrometry using a Hewlett-Packard chromatograph equipped with a 30 m DB-17 capillary column (210°C (30 min) to 240°C at 2°C/min). Mass spectrometry in the electron impact mode was recorded using a Varian Saturn II mass spectrometer. Linkage data were interpreted based upon the previously
- 15 published structure of the R1 core (Holst, O. and Brade, H. 1992), as described for analysis of the R1 outer core assembly (Heinrichs, D.E., et al. 1998). Methylation linkage analyses were carried out by the procedure of Ciucanu and Kerek (Ciucanu, I. and Kerek, F., 1984). The permethylated alditol acetate derivatives were fully characterized by GLC-mass spectrometry in the electron impact mode using a column of
- 20 DB-17 operated isothermally at 190°C for 60 min.

*Fast Atom Bombardment-Mass Spectrometry (FAB-MS)* - A fraction of the methylated sample from the linkage analysis was taken for positive ion FAB-MS, which was performed using a Jeol JMS-AX505H mass spectrometer with glycerol/thioglycerol as the matrix, and a tip voltage of 3 kV.

- 25 *<sup>31</sup>P-NMR Spectroscopy* - <sup>31</sup>P-NMR or phosphorus nuclear magnetic resonance spectra were recorded with a Bruker DRX 400 MHz instrument at 161.98 MHz with *ortho*-phosphoric acid as the external reference (0.0 ppm) and with p1=30 in the proton-decoupling mode. Prior to performing the NMR experiments, the samples were lyophilized three times in <sup>2</sup>H<sub>2</sub>O (99.9%). The p<sup>2</sup>H was adjusted with triethylamine
- 30 when necessary.

#### Example 1

- Structural analysis of the core OS from the R1 prototype strain, F470* - The established structure of the F470 core OS (Fig. 2A) served as a framework for the interpretation of the results. Sugar composition analysis detected the presence of all the expected core
- 35 OS sugars (glucose, galactose, and heptose, data not shown). Methylation linkage analysis of the core OS from F470 showed all of the permethylated alditol acetate derivatives from the outer core residues in the ratios expected (Fig. 3A and Table I). No peaks were observed in the GLC chromatogram (Fig. 3A) for the derivatives from

either HepI or HepII because the phosphoryl substituents attached to these residues (Fig. 2A) made their derivatives too polar to elute from the column. This proved useful in subsequent analyses because it allowed the loss of phosphoryl substituents from HepI and HepII to be monitored as the appearance of either a 3-substituted or 3,7-disubstituted heptose derivative peak in the GLC chromatogram.

<sup>31</sup>P-NMR spectroscopy of the F470 core OS at p<sup>2</sup>H 8.5 yielded the spectrum shown in Fig. 3E. The signal at 5 ppm is indicative of a phosphomonoester (phosphate ("P") on either HepI or HepII), while the two peaks near -10 ppm are characteristic of a diphosphodiester (2-aminoethyldiphosphate ("PPEtN") on HepI (Hep = L-glycero-D-manno-heptose)) (Helander, I.M. et al., 1994). At lower solvent p<sup>2</sup>H values, the peak at 5 ppm was shifted upfield (data not shown), confirming its assignment as a phosphomonoester (Helander, I.M. et al., 1994). The ratio of P to PPEtN in the F470 core OS was estimated by the relative peak heights in Fig. 3E. As expected, there was more P than PPEtN, since HepII is only substituted with P while HepI is either substituted with P or PPEtN.

#### Example 2

*Sequence analysis and mutagenesis of waaY* - Pairwise nucleotide alignments of the *waaY* coding region from *E. coli* K-12, R1, R2, and R4, and *S. enterica* serovar Typhimurium (all of the core types for which DNA sequence of the *waa* loci was available) showed identities ranging from 59.4 - 99.0%. Multiple alignment of the predicted WaaY proteins showed high total similarity (85.3%) but much lower identity (43.1%). In BLASTP searches of the available databases, WaaY showed no significant homologies to other characterized proteins. However, using the PSI-BLAST server analysis program, queries with the various WaaY protein sequences suggested biologically relevant similarities to a large number of kinases (data not shown). This circumstantial data suggested a potential role for WaaY in phosphorylation reactions.

To test this possibility, strain CWG312 was derived by insertion of the *aacC1* gene into the unique *Sna*BI site in the *waaY* coding region of F470 (Fig. 2B). The LPS from the resulting mutant migrated similarly to that of the F470 parent in sodium dodecyl sulphate-polyacrylamine gel electrophoresis (SDS-PAGE) (data not shown), precluding any significant effect of the mutation on core OS extension. However, the minimum inhibitory concentration (MIC) of SDS and of novobiocin for CWG312 were slightly less than for F470 (Table II), suggesting subtle changes in outer membrane properties.

#### Example 3

*Structural analysis of the CWG312 core OS and assignment of WaaY function* -The structure of the deduced CWG312 core OS is shown in Table I. Sugar composition

analysis detected the presence of all the core OS sugars found in F470 (data not shown). Linkage analysis of CWG312 resulted in a GLC chromatogram that was identical to that from the F470 parent (compare Fig. 3A and B) except for the appearance of a peak (peak 9, Fig. 3B) corresponding to a 3,7-disubstituted heptose derivative (Table I).

5 Based on the F470 structure, this derivative must result from unphosphorylated HepII. <sup>31</sup>P-NMR spectroscopy further corroborated the loss of P from the CWG312 core OS: in the F470 parent there was more P than PPEtN, but in CWG312 there was slightly more PPEtN than P (compare Fig. 3E and F). The observed shift in the ratio of P to PPEtN is explained by the loss of P from HepII, leaving only P and PPEtN on HepI. Therefore, given the disappearance of P from HepII in the CWG312 core OS and the biologically significant sequence similarity of WaaY to some kinases, WaaY is concluded to be involved in the phosphorylation of HepII.

#### Example 4

*Sequence analysis and mutagenesis of waaQ* - In *E. coli* K-12, R1, R2, and R4, and in *S. enterica* serovar Typhimurium, *waaQ* is the first gene of the central operon of the core OS biosynthesis region (Fig. 2B). Pairwise nucleotide alignments of the *waaQ* genes from these core types showed identities ranging from 68.5 - 98.6%. Multiple sequence alignment of the predicted WaaQ proteins reflected the homology observed at the nucleotide level with a total similarity of 88.1% (64.0% identity). The predicted WaaQ proteins showed limited homology to both WaaC (40.6% total similarity, 10.8% identity) and WaaF (50.1% total similarity, 16.5% identity), the HepI (Kadrmaz, J.L. and Raetz, C.R., 1998) and HepII transferases, respectively (Fig. 2A).

Strain CWG297 was derived by insertion of the *aacC1* gene into the unique *NruI* site in the *waaQ* coding region of F470 (Fig. 2B). The LPS from the resulting mutant migrated similarly to that of the F470 parent in SDS-PAGE (data not shown), but the MIC of SDS and of novobiocin for CWG297 were slightly less than for F470 (Table II) and comparable with the values for the *waaY* mutant, CWG312.

#### Example 5

*Structural analysis of the CWG297 core OS and assignment of WaaQ function* - Sugar composition analysis detected the presence of all the core OS sugars found in F470 (data not shown). The structure of the CWG297 core OS shown in Table I was deduced from methylation linkage analysis and <sup>31</sup>P-NMR spectroscopy as follows. Firstly, methylation linkage analysis of the CWG297 core OS showed all of the outer core derivatives in the expected ratios (Table I), but the terminal heptose derivative (resulting from HepIII) was completely absent (note the absence of peak 6 in Fig. 3C). The disappearance of the HepIII side branch was also confirmed by FAB-MS (data not shown). Given the similarity of WaaQ to WaaC and WaaF (the HepI and HepII transferases respectively, Fig. 2A) and the complete absence of HepIII in the CWG297

core OS, it was concluded that *waaQ* encodes the transferase for the branch HepIII residue. Interestingly, the appearance of a 3-linked heptose derivative in the linkage analysis of CWG297 (peak 8, Fig. 3C) also indicated the loss of a phosphoryl substituent from either HepI or HepII (both are 3-linked after the loss of HepIII) due to the *waaQ* mutation. To resolve which heptose residue was lacking its phosphoryl substituent, the <sup>31</sup>P-NMR spectrum of the CWG297 core OS was compared to the spectra from F470 and CWG312 (*waaY*). Given the similar P to PPEtN ratios for CWG297 and CWG312 (compare Fig. 3F and G) it was concluded that the same phosphoryl substituent (P on HepII) was absent in both strains. If the *waaQ* mutation had affected phosphoryl substitution of HepI, the ratio of P relative to PPEtN would have increased rather than decreased. The observed loss of P from HepII in CWG297 did not contradict the assignment of WaaQ as the HepIII transferase since WaaY had already been assigned as the enzyme responsible for the phosphorylation of HepII (see above). Rather, the transfer of HepIII by WaaQ appears to be a prerequisite to the phosphorylation of HepII catalyzed by WaaY.

#### Example 6

*Sequence analysis and mutagenesis of waaP* - In *E. coli* K-12, R1, R2, and R4, and in *S. enterica* serovar Typhimurium, *waaP* occurs as the third gene of the central operon of the core OS biosynthesis region (Fig. 2B). Pairwise nucleotide alignments indicated that the *waaP* gene from these core types was highly conserved (71.8 - 98.1% identity). Similarity at the protein level was even higher, with multiple sequence alignment of the predicted WaaP proteins showing a total similarity of 93.3%, and 75.9% identity. In BLASTP searches of the available databases, WaaP showed no significant similarity to other characterized proteins, as previously reported (Schnaitman, C.A. and Klena, J.D., 1993; Parker, C.T. et al., 1992). However, the recently developed PSI-BLAST server analysis program again identified biologically relevant similarities shared between the various WaaP proteins and a large number of kinases (data not shown). In experiments based on information about catalytic bases in kinases in the public domain, (i.e., site-directed mutagenesis and crystallography data from protein kinases in other organisms<sup>2,3</sup>) we mutated an amino acid predicted to function as the enzyme's catalytic base. Using a PCR-based site-directed mutagenesis protocol, (see General Methods herein) we mutated aspartate (D) 162 to an alanine (A) residue on plasmid pWQ909<sup>4</sup>, which contains *waaP* cloned behind an arabinose-inducible promoter. Plasmid pWQ909 and pWQ909(D162A) were then electroporated into our defined *E. coli waaP* mutant strain to determine their ability to complement its deep-rough phenotype. The results (not shown) clearly indicate that aspartate 162 is an essential residue, and support our proposal that WaaP functions like a kinase.]

Strain CWG296 was derived by insertion of the *aacC1* gene into the unique *NruI* site in the *waaP* coding region of F470 (Fig. 2B). The resulting mutant was hypersensitive to novobiocin and SDS (Table II), as expected based on results from previous studies (Helander, I.M. et al., 1989; Parker, C.T. et al., 1992). Introduction of multicopy *waaP* (on plasmid pWQ909) into CWG296 restored wild-type levels of resistance to these hydrophobic agents (Table II).

#### Example 7

*Structural analysis of the CWG296 core OS and assignment of WaaP function* - Sugar composition analysis detected the presence of all the core OS sugars found in F470 (data not shown). The structure of the CWG296 core OS shown in Table I was deduced from methylation linkage analysis and <sup>31</sup>P-NMR spectroscopy as follows. Firstly, <sup>31</sup>P-NMR spectroscopy showed a complete lack of phosphorus in the CWG296 core OS (Fig. 3H), indicating that mutation of *waaP* resulted in the loss of all phosphoryl substituents from HepI and HepII. The GLC chromatograms from the CWG296 and F470 methylation linkage analyses were then compared to determine any other effects of the *waaP* mutation on the core OS structure. Of note, the terminal heptose derivative from HepIII was almost completely absent in the CWG296 core OS (note the absence of peak 6 in Fig. 3D). This lack of terminal heptose was also observed by FAB-MS (data not shown), and implicated the *waaP* mutation in the loss of HepIII in addition to the above-mentioned deficiency in phosphoryl substituents. The absence of phosphoryl substituents and of HepIII was further corroborated by the appearance of a large peak in the CWG296 GLC chromatogram (peak 8, Fig. 3D) corresponding to a 3-substituted heptose derivative from HepI and HepII. The calculated molar ratio of this derivative (Table I) was somewhat lower than expected, but the observed signal was clearly twice that from CWG297 (compare peak 8 in Fig. 3C and D, and Table I), as expected based on their predicted structures. (The prolonged retention time of the 3-substituted heptose derivative on the GLC column may account for this slight discrepancy in molar ratios.) Finally, the amounts of terminal glucose (from the β-Glc side branch) and of 2,3-disubstituted glucose (from GlcII where Glc = D-Glucose) were noticeably decreased in CWG296 (compare peaks 1 and 7 in Fig. 3A and D, and see Table I). The decrease in 2,3-disubstituted glucose was offset by the appearance of an approximately equal amount of 2-substituted glucose (note the appearance of peak 3, Fig. 3D), reflecting GlcII lacking the β-Glc substitution.

In summary, the mutation of *waaP* resulted in a core OS which was devoid of all phosphoryl substituents and the branch HepIII residue, and which appeared to contain a lower percentage of β-Glc substituted GlcII. Since WaaY and WaaQ had already been assigned in this study as the enzymes responsible for the phosphorylation of HepII and the transfer of HepIII respectively (see above), and

since WaaV had been previously assigned as the  $\beta$ -Glc transferase (see Fig. 2A, and Heinrichs, D.E. et al., 1998), it is concluded that the enzyme encoded by *waaP* is responsible for the phosphoryl substitution of HepI. This conclusion is supported by the sequence similarity of WaaP to known kinases, first reported in this study. The  
5 loss of other substituents and sugar residues from the CWG296 core OS does not contradict this assignment, but suggests that the activity of WaaP is a prerequisite to the efficient functioning of other enzymes.

#### Discussion

The data presented here identify WaaY as the enzyme which phosphorylates  
10 HepII, WaaQ as the transferase for the branch HepIII residue, and WaaP as the enzyme responsible for the addition of either P or PPEtN to HepI. With these assignments, a function has now been ascribed to every gene in the *waaQ* operon of the core OS biosynthesis region in the *E. coli* R1 prototype strain, F470 (see Fig. 2A). Moreover, the deduced structures of the core OSs from the *waaY*, *Q*, and *P* mutants are  
15 consistent with a sequence of events in the decoration of the heptose region of the core OS where 1) WaaP adds P or PPEtN to HepI; 2) WaaQ adds HepIII to HepII; and 3) WaaY adds P to HepII.

The conclusion that the activity of WaaP is a prerequisite to the functioning of both WaaQ and WaaY is based on the fact that the core OS of CWG296 (*waaP*) does  
20 not have HepIII or a P substituent on HepII (Table I) even though functional copies of the *waaQ* and *waaY* genes are present on the chromosome. Likewise, the activity of WaaQ is concluded to be required prior to the functioning of WaaY because the core OS of CWG297 (*waaQ*) does not have the P substituent on HepII (Table I) even though the *waaY* gene in this mutant is fully functional. These results can be explained by a  
25 fastidious substrate requirement in each sequential reaction, such that WaaQ can only effect the transfer of HepIII to a lipid A-core acceptor with P or PPEtN on HepI, and WaaY can only phosphorylate HepII if the lipid A-core acceptor has both HepIII and a phosphoryl substituent on HepI. Alternatively, these data could reflect a requirement for specific protein-protein interactions to provide a functional  
30 multi-enzyme complex.

The data presented here provide an explanation for the multiple functions attributed to *waaP* in the literature. For example, the suggested involvement of WaaP in the transfer of HepIII in *E. coli* K-12 (Parker, C.T. et al., 1992) has now been resolved: WaaQ is the HepIII transferase, but requires the prior functioning of WaaP.  
35 It had previously been suggested, based solely on limited predicted protein sequence similarities, that the product of *waaQ* might encode the HepIII transferase (Schnaitman, C.A. and Klena, J.D., 1993). This study provides the first genetic and structural data to support this claim. Another reported effect of *waaP* mutations in *S. enterica* serovars Minnesota and Typhimurium (Helander, I.M. et al., 1989) is a

truncation of the core OS distal to GlcI (Fig. 1); however, the precisely defined, non-polar *waaP* mutations derived in this study clearly show that core extension is complete, although there is a reduction in the efficiency of branch  $\beta$ -Glc substitution. The core truncation observed in the '*waaP*' mutants of *S. enterica* could be explained by polar or multiple mutations which eliminate the function of downstream genes.

The contribution of the heptose region phosphoryl substituents to outer membrane stability is clearly shown by novobiocin and SDS sensitivity testing, as illustrated in Table II. The lack of P on HepII in CWG312 (*waaY*) and in CWG297(*waaQ*) resulted in a minor increase in the sensitivity of these strains to the hydrophobic agents. However, the complete lack of phosphoryl substituents in the core OS of CWG296 (*waaP*) resulted in a 32-fold increase in the susceptibility to novobiocin, and more than a 1000-fold increase in the susceptibility to SDS. Therefore, only the complete loss of phosphoryl substituents from the heptose region of the core was sufficient to cause the characteristic hypersensitivity to hydrophobic agents associated with the deep-rough phenotype. It is noteworthy that the negative charges required for LPS crosslinking need not come from phosphoryl substituents: for example, the core OS of *Klebsiella pneumoniae* is devoid of phosphate, but contains negatively-charged galacturonic acid residues instead (Süsskind, M. et al., 1995; Severn, W.B. et al., 1996).

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

## FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

- Vaara, M. (1992) *Microbiol. Rev.* 56, 395-411.
- 5 Whitfield, C., Amor, P. A., and Köplin, R. (1997) *Mol. Microbiol.* 23, 629-638.
- Raetz, C. R. H. (1996) in *Escherichia coli and Salmonella. Cellular and Molecular Biology* (Neidhardt, F. C., Curtiss III, R., Ingraham, J. L., Lin, E. C. C., Low, K. B., Magasanik, B., Reznikoff, W. S., Riley, M., Schaechter, M., and Umberger, H. E., eds) Vol. 1, pp. 1035-1063, ASM Press, Washington, D.C.
- 10 Holst, O., and Brade, H. (1992) in *Bacterial Endotoxic Lipopolysaccharides* (Morrison, D. C., and Ryan, J. L., eds) Vol. I, pp. 134-170, CRC Press, Boca Raton, FL.
- 15 Olsthoorn, M. M. A., Petersen, B. O., Schlecht, S., Haverkamp, J., Bock, K., Thomas-Oates, J. E., and Holst, O. (1998) *J. Biol. Chem.* 273, 3817-3829.
- Whitfield, C., Keenleyside, W. J., and Clarke, B. R. (1994) in *Escherichia coli in domestic animals and man*. (Gyles, C. L., ed), pp. 437-494, CAB International.
- Helander, I. M., Vaara, M., Sukupolvi, S., Rhen, M., Saarela, S., Zähringer, U., and Mäkelä, P. H. (1989) *Eur. J. Biochem.* 185, 541-546.
- 25 Nikaido, H. (1996) in *Escherichia coli and Salmonella. Cellular and Molecular Biology*. (Neidhardt, F. C., Curtiss III, R., Ingraham, J. L., Lin, E. C. C., Low, K. B., Magasanik, B., Reznikoff, W. S., Riley, M., Schaechter, M., and Umberger, H. E., eds) Vol. 1, pp. 29-47, ASM Press, Washington, D.C.
- Schnaitman, C. A., and Klena, J. D. (1993) *Microbiol. Rev.* 57, 655-682.
- Nikaido, H., and Vaara, M. (1985) *Microbiol. Rev.* 49, 1-32.
- Dröge, W., Ruschmann, E., Lüderitz, O., and Westphal, O. (1968) *Eur. J. Biochem.* 4, 134-138.
- Mühlradt, P., Risse, H. J., Lüderitz, O., and Westphal, O. (1968) *Eur. J. Biochem.* 4, 139-145.
- 40 Parker, C. T., Kloser, A. W., Schnaitman, C. A., Stein, M. A., Gottesman, S., and Gibson, B. W. (1992) *J. Bacteriol.* 174, 2525-2538.
- Gibb, A. P., Barclay, G. R., Poxton, I. R., and di Padova, F. (1992) *J. Infect. Dis.* 166, 1051-1057.
- 45 Jansson, P.-E., Lindberg, A. A., Lindberg, B., and Wollin, R. (1981) *Eur. J. Biochem.* 115, 571-577.
- Heinrichs, D. E., Yethon, J. A., and Whitfield, C. (1998) submitted.
- 50 Schmidt, G., Jann, B., and Jann, K. (1969) *Eur. J. Biochem.* 10, 501-510.
- Schweizer, H. P. (1993) *BioTechniques* 15, 831-833.
- 55 Hamilton, C. A., Aldea, M., Washburn, B. K., Babtizke, P., and Kushner, S. R. (1989) *J. Bacteriol.* 171, 4617-4622.
- Amor, P. A., and Whitfield, C. (1997) *Mol. Microbiol.* 26, 145-161.

- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*. 2nd edition., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- 5 Guzman, L.-M., Belin, D., Carson, M. J., and Beckwith, J. (1995) *J. Bacteriol.* 177, 4121-4130.
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) *J. Mol. Biol.* 215, 403-410.
- 10 Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997) *Nucl. Acids Res.* 25(17), 3389-3402.
- Westphal, O., and Jann, K. (1965) *Meth. Carbohydr. Chem.* 5, 83-91.
- 15 Sawardeker, J. H., Sloneker, J. H., and Jeanes, A. (1967) *Anal. Chem.* 39, 1602-1604.
- Ciucanu, I., and Kerek, F. (1984) *Carbohydr. Res.* 131, 209-217.
- Helander, I. M., Kilpeläinen, I., and Vaara, M. (1994) *Mol. Microbiol.* 11, 481-487.
- Kadrmaz, J. L., and Raetz, C. R. (1998) *J. Biol. Chem.* 273, 2799-2807.
- Sirisena, D. M., MacLachlan, P. R., Liu, S.-L., Hessel, A., and Sanderson, K. E. (1994) *J. Bacteriol.* 176, 2379-2385.
- Brabetz, W., Müller-Leonnies, S., Holst, O., and Brade, H. (1997) *Eur. J. Biochem.* 247, 716-724.
- Parker, C. T., Pradel, E., and Schnaitman, C. A. (1992) *J. Bacteriol.* 174, 930-934.
- Süsskind, M., Müller-Leonnies, S., Nimmich, W., Brade, H., and Holst, O. (1995) *Carbohydr. Res.* 269, C1-C7.
- 35 Severn, W. B., Kelly, R. F., Richards, J. C., and Whitfield, C. (1996) *J. Bacteriol.* 178, 1731-1741.

## DETAILED LEGENDS FOR VARIOUS FIGURES

Figure 1. Generalized structure of the lipid A-core portion of lipopolysaccharide common to *E. coli* and *S. enterica*, highlighting the heptose region. Core residues are designated by sugar abbreviation and number to facilitate identification. The abbreviations are as follows: *GlcN*, D-glucosamine; *P*, phosphate; *Kdo*, 3-deoxy-D-manno-oct-2-ulonic acid; *Hep*, L-glycero-D-manno-heptose; *PPeN*, 2-aminoethyl diphosphate; *Glc*, D-glucose; *Hex*, D-hexose (either glucose or galactose). \*, structural differences between the five *E. coli* and two *S. enterica* core types are due to differences between the HexII and HexIII sugars, and to the nature and positions of side-branch substitutions of GlcI, HexII, and HexIII.

Figure 2. Structure of the R1 core OS of *E. coli* F470, and genetic organization of the *waa* locus indicating the locations of the non-polar insertion mutations. A, structure of the core OS isolated from acetic acid-hydrolyzed F470 LPS (mild acid hydrolysis cleaves both the KdoI-26'-lipid A and KdoII-24-KdoI linkages). All sugars are in the pyranose configuration and the linkages are  $\alpha$  unless otherwise indicated. The data which identify the genetic determinants for the modification of the heptose region (enclosed in boxes) are reported in this study. The assignment of function to other genes has been reported previously (Heinrichs, D.E. et al., 1998; Kadrmaz, J.L. and Raetz, C.R., 1998; Brabetz, W., et al., 1997). B, map of the R1 core OS biosynthesis region (*waa* locus) indicating the insertion site for the *aacC1* gene cassette (represented by an open triangle) in each of the F470 derivatives. The CWG\*\*\* designations for each derivative strain are indicated above the triangles. Only the restriction endonuclease sites used for mutagenesis are shown. The *waaF* gene (encoding the HepII transferase) lies just upstream of *waaC* in both *E. coli* K-12 and *S. enterica* serovar Typhimurium, but sequence data for this region in *E. coli* R1 is not currently available.

Figure 3. Methylation linkage analyses and  $^{31}\text{P}$ -NMR spectroscopy of the core OSs from F470 and derivatives. A-D, GLC chromatograms from the methylation linkage analyses of A, F470; B, CWG312; C, CWG297; and D, CWG296. The numbered peaks correspond to the permethylated alditol acetate derivatives from 1) terminal Glc (5.8 min); 2) terminal Gal (6.2 min); 3) 2-substituted Glc (7.3 min); 4) 3-substituted Glc (7.5 min); 5) 2-substituted Gal (7.8 min); 6) terminal Hep (8.6 min); 7) 2,3-disubstituted Glc (9.2 min); 8) 3-substituted Hep (11.0 min); and 9) 3,7-disubstituted Hep (14.0 min). The approximate molar ratios of these derivatives are shown in Table I. E-H,  $^{31}\text{P}$ -NMR spectra of the core OSs from E, F470; F, CWG312; G, CWG297; and H, CWG296. The signal at 5 ppm is indicative of a phosphomonoester (P on either HepI or HepII), and

the two peaks near -10 ppm are characteristic of a diphosphodiester (PPEtN on HepI) (Helander, I.M. et al., 1994).

**TABLE I**  
Structures of the core OSs from F470 and derivatives as deduced from linkage analyses

The peaks in the GLC chromatograms from the linkage analyses (Fig. 3A-D) were correlated to the substituted sugar residues from which they were derived. Approximate molar ratios were calculated from the integrated peak areas. The published structure of the F470 core OS (Fig. 2A) was used as a framework for the interpretation of results as discussed in the text.

Strain	Peak	Linkage	Approximate Molar Ratio	Core OS Structure			
F470 (parent)	1	Glc(1→	1.0	Hep III			
	2	Gal(1→	1.0	↓			
	4	→3)-Glc(1→	0.7	7			
	5	→2)-Gal(1→	1.3	Gal I-1→2-Glc II-1→3-Glc I-1→3-Hep II-1→3-Hep I-1→			
	6	Hep(1→	0.6	2	3	4	4
	7	→2,3)-Glc(1→	1.0	↑	↑	↑	↑
				1	1	P	P/PPEN
				Gal II	β-Glc		
CWG312 (waaY)	1	Glc(1→	0.9	Hep III			
	2	Gal(1→	0.8	↓			
	4	→3)-Glc(1→	1.1	7			
	5	→2)-Gal(1→	1.0	Gal I-1→2-Glc II-1→3-Glc I-1→3-Hep II-1→3-Hep I-1→			
	6	Hep(1→	0.7	2	3	4	4
	7	→2,3)-Glc(1→	1.1	↑	↑	↑	↑
	9	→3,7)-Hep(1→	1.1	1	1	P/PPEN	
				Gal II	β-Glc		
CWG297 (waaQ)	1	Glc(1→	0.9	Gal I-1→2-Glc II-1→3-Glc I-1→3-Hep II-1→3-Hep I-1→			
	2	Gal(1→	1.0	2	3	4	4
	4	→3)-Glc(1→	1.1	↑	↑	↑	↑
	5	→2)-Gal(1→	1.0	1	1	P/PPEN	
	7	→2,3)-Glc(1→	1.1	Gal II	β-Glc		
	8	→3)-Hep(1→	0.7				
CWG296 (waaP)	1	Glc(1→	0.5	Gal I-1→2-Glc II-1→3-Glc I-1→3-Hep II-1→3-Hep I-1→			
	2	Gal(1→	0.9	2	3		
	3	→2)-Glc(1→	0.7	↑	↑		
	4	→3)-Glc(1→	1.0	1	1		
	5	→2)-Gal(1→	1.1				
	7	→2,3)-Glc(1→	0.6	Gal II	β-Glc <sup>a</sup>		
	8	→3)-Hep(1→	1.1				

<sup>a</sup> in CWG296, the β-Glc residue is only present in about 50% of the core OSs.

TABLE II

Minimum inhibitory concentration (MIC) of SDS and novobiocin for F470 and derivatives.

Strain	MIC	
	SDS (mg/mL)	novobiocin ( $\mu$ g/mL)
F470 (parent)	>200	200
CWG312 ( <i>waaY</i> )	200	100
CWG297 ( <i>waaQ</i> )	200	100
CWG296 ( <i>waaP</i> )	0.1	6.3
CWG296 ( <i>waaP</i> ) +pWQ909	200	100

We Claim:

1. An isolated nucleic acid molecule containing a sequence encoding a protein having the activity associated with a WaaP protein.
2. A nucleic acid sequence according to claim 1 having a sequence shown in SEQ. ID. NO.: 1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5.
3. An isolated nucleic acid molecule according to claim 1 comprising:
  - 10 (a) a nucleic acid sequence as shown in SEQ.ID.NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5; wherein T can also be U;
  - (b) nucleic acid sequences complementary to (a);
  - (c) nucleic acid sequences which are homologous to (a) or (b);
  - (d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30  
15 bases, and which will hybridize to (a) to (d) under stringent hybridization conditions;  
or
  - (e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.
- 20 4. An isolated protein having the activity of the WaaP protein.
5. A protein according to claim 4 having the amino acid sequence shown in SEQ.ID.NO.:2 or SEQ.ID.NO.:4 or SEQ.ID.NO.:6.
- 25 6. A method of preventing or treating a gram negative bacterial infection comprising administering an effective amount of a substance that inhibits WaaP to an animal in need thereof.
7. The method of claim 6 wherein the bacterial infection is caused by  
30 bacteria selected from the group consisting of *Salmonella enterica*, *Escherichia coli*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Shigella flexneri*, *Shigella dysenteriae*, and *Pseudomonas aeruginosa* serotypes 02, 05, 16, 18 and 20, *P. aeruginosa* serotypes 03 or 06 and other members of the family Pseudomonadaceae.
- 35 8. The method of claim 6 wherein the inhibitor is selected from the group consisting of an antibody to the activity of the WaaP protein; an antisense oligonucleotide which inhibits translation of the *waaP* gene; or an antibody which inhibits the interaction of substrate of the WaaP protein and the WaaP protein.

SUBSTITUTE SHEET (RULE 26)


9. The antisense oligonucleotide of claim 8 wherein the oligonucleotide is complimentary to a nucleic acid sequence from a *waaP* gene.
10. The method of any one of claims 6 to 9 wherein the bacterial infection is in an animal.
11. A method for assaying for inhibitors of WaaP activity in gram negative pathogens under appropriate conditions comprising the steps of incubating a gram negative pathogen in the presence of a test substance and assaying for WaaP activity and comparing the results to control results.
12. A vaccine for preventing or treating a gram negative bacterial infection comprising an effective amount of a WaaP protein.
13. The vaccine of claim 12 where the WaaP protein is in admixture with a suitable diluent or carrier.
14. A method of preventing or treating a gram negative bacterial infection comprising administering a vaccine containing an effective amount of a WaaP protein, to an animal in need thereof.
15. The method of claim 14 wherein the WaaP protein is in admixture with a suitable diluent or carrier.
16. A composition for use in the attenuation of a virulent gram negative pathogen in an animal, comprising an inhibitor of WaaP activity .
17. The composition of claim 16 wherein the inhibitor is in admixture with a pharmaceutically acceptable diluent or carrier .
18. An inhibitor of WaaP activity in a gram negative pathogen.
19. The inhibitor of claim 18 wherein the pathogen is selected from the group consisting of *Salmonella enterica*, *Escherichia coli*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Shigella flexneri*, *Shigella dysenteriae*, *Pseudomonas aeruginosa* serotypes 02, 05, 16, 18 and 20, *P. aeruginosa* serotypes 03 or 06 or other members of the family Pseudomonadaceae.
20. The inhibitor of claim 18 which is a specific antibody to WaaP.

SUBSTITUTE SHEET (RULE 26)



21. The inhibitor of claims 18 which inhibits translation of the *waaP* gene.
- 5 22. The inhibitor of claim 21 which is an antisense oligonucleotide.
23. The inhibitor of claim 18 which inhibits interaction of substrate of the WaaP protein with the WaaP protein.
- 10 24. The inhibitor of claim 23 which is a specific antibody.

SUBSTITUTE SHEET (RULE 26)


1/9

FIGURE 1

2/9

FIGURE 2AFIGURE 2B

3/9

FIGURE 3

SUBSTITUTE SHEET (RULE 26)

4/9

FIGURE 4

LOCUS R1RFAP 795 BP DS-DNA

BASE COUNT 209 A 172 C 207 G 207 T 0 OTHER  
ORIGIN

```
1 ATGGTTGAAC TTAAAGAGCC GTTTGCCACG TTATGGCGCG GCAAAGATCC TTTTGAGGAA
61 GTTAAACCT TGCAGGGTGA GGTATTTCTGT GAACTGGAAA CTCGCCGTAC TCTGCGCTTT
121 GAAATGGCGG GCAAAAGCTA TTTTCTCAA TGGCATCGCG GCACGACCCT GAAAGAGATA
181 ATCAAAAATT TACTCTCATT GCGGATGCCA GTATTAGGCG CTGACCGCGA ATGGAATGCG
241 ATTCATCGAC TCGGGGATGT CGGCGTTGAT ACTATGTATG GGGTGGCATT TGGCGAAAAA
301 GGCATGAATC CGCTGACCAG AACTTCATTT ATTATTACCG AAGATCTGAC ACCAACCATA
361 AGTCTGGAAG ATTACTGTGC TGACTGGGCG ACTAACCTC CAGATGTTTCG CGTAAAGCGT
421 ATGCTTATTA AGCGTGTCGC GACGATGGTG CGCGATATGC ATGCTGCGGG CATTAACCAC
481 CGTGACTGTT ATATCTGTCA TTTCTGCTG CACTTGCCTT TTTCCGGTAA GGAAGAGGAG
541 TTAAAAATTT CGGTAATTGA CCTGCACCGG GCGCAGCTTC GCACGCGCGT TCCACGTCGT
601 TGGCGGGATA AAGATCTTAT TGGGCTTTAT TTTTCTTCGA TGAATATCGG CCTGACTCAG
661 CGGGATATCT GCGGTTTAT GAAAGTGTAT TTTGCCGCCC CGCTTAAAGA CATTCTCAAG
721 CAGGAACAAG GACTGCTGTC GCAAGCAGAA GCAAAAGCCA CAAAATCAG GGAAAGAACG
781 ATTCGAAAAT CGTTG
```

SUBSTITUTE SHEET (RULE 26)

5/9

FIGURE 5

LOCUS	RFAP R1	265 AA	PROT
Peptide	1	265	1 to 795 of RlrfaP (translated)
ORIGIN			
1	MVELKEPFAT	LWRGKDPFEE	VKTLOQEVFR ELETTRTLRF EMAGKSYFLK WHRGTTLKEI
61	IKNLLSLRMP	VLGADREWNA	IHRLRDVGVD TMYGVAFGEK GMNPLTRTSF IITEDLTPTI
121	SLEDYCADWA	TNPPDVRVKR	MLIKRVATMV RDMHAAGINH RDCYICHFLL HLPFSGKEEE
181	LKISVIDLHR	AQLRTRVPRR	WRDKDLIGLY FSSMNIGLTQ RDIWRFMKVY FAAPLKDILK
241	QEQGLLSQAE	AKATKIRERT	IRKSL

6/9

FIGURE 6

LOCUS	R3 RFAP	795 BP DS-DNA				
BASE COUNT	210 A	172 C	206 G	207 T	0 OTHER	
ORIGIN						
1	ATGGTTGAAC	TTAAAGAGCC	GTTTGCCACG	TTATGGCGCG	GCAAAGATCC	TTTTGAGGAA
61	GTAAAAACCT	TGCAGGGTGA	GGTATTTTCGT	GAAGTGGAAA	CTCGCCGTAC	TCTGCGCTTT
121	GAAATGGCGG	GCAAAAGCTA	TTTTCTCAAA	TGGCATCGCG	GCACGACCCT	GAAAGAGATA
181	ATCAAAAATT	TACTCTCATT	GCGGATGCCA	GTATTAGGCG	CTGACCGCGA	ATGGAATGCG
241	ATTCATCGAC	TGCGGGATGT	CGGCGTTGAT	ACTATGTATG	GGGTGGCATT	TGGCGAAAAA
301	GGCATGAATC	CGCTGACCAG	AACTTCATTT	ATTATTACCG	AAGATCTGAC	ACCAACCATA
361	AGTCTTGAAG	ATTACAGTGC	TGACTGGGCG	ACTAACCCTC	CAGATGTTTCG	CGTAAAGCGT
421	ATGCTTATTA	AGCGTGTCGC	GACGATGGTG	CGCGATATGC	ATGCTGCGGG	CATTAACCAC
481	CGTGACTGTT	ATATCTGTCA	TTTCCTGCTG	CACTTGCCTT	TTTCCGGTAA	GGAAGAGGAG
541	TTAAAAATTT	CGGTAATTGA	CCTGCACCGG	GCGCAGCTTC	GCACGCGCGT	TCCACGTCGT
601	TGGCGGGATA	AAGATCTTAT	TGGGCTTTAT	TTTTCTTCGA	TGAATATCGG	CCTGACTCAG
661	CGGGATATCT	GGCGGTTTAT	GAAAGTGTAT	TTTGCCGCCC	CGCTTAAAGA	CATTCTCAAG
721	CAGGAACAAG	GACTGCTGTC	GCAAGCAGAA	GCAAAAAGCCA	CAAAAATCAG	GGAAAGAACG
781	ATTCGAAAAT	CGTTG				

7/9

FIGURE 7

LOCUS RFAP R3 265 AA PROT

FEATURES	From	To/Span	Description
Peptide	1	265	1 to 795 of R3 rfaP (translated)

ORIGIN

1	MVELKEPFAT	LWRGKDPFEE	VKTLQGEVFR	ELETRRTLRF	EMAGKSYFLK	WHRGTTLKEI
61	IKNLLSLRMP	VLGADREWNA	IHRLRDVGVD	TMYGVAFGK	GMNPLTRTSF	IITEDLTPTI
121	SLEDYSADWA	TNPPDVRVKR	MLIKRVATMV	RDMHAAGINH	RDCYICHFLL	HLPFSGKEEE
181	LKISVIDLHR	AQLRTRVPRR	WRDKDLIGLY	FSSMNIGLTQ	RDIWRFMKVY	FAAPLKDILK
241	QEQGLLSQAE	AKATKIRERT	IRKSL			

SUBSTITUTE SHEET (RULE 26)

8/9

FIGURE 8

LOCUS	R4RFAP	795 BP DS-DNA				
FEATURES	From	To/Span	Description			
frag	795	1 (C)	6854 to 7648 of F2513rfaC-kdtA			
BASE COUNT	212 A	177 C	204 G	202 T	0 OTHER	
ORIGIN						
1	ATGGTTGAAC	TTAAAGAGCC	GTTTGCCACG	TTATGGCGCG	GTAAAGATCC	TTTTGAGGAA
61	GTAAAAACCT	TGCAGGGTGA	GGTATTTTCGT	GAACTGGAAA	CTCGCCGCAC	TCTGCGCTTT
121	GAAATGGCGG	GCAAAAGCTA	TTTTCTCAAA	TGGCATCGCG	GCACGACCCCT	GAAAGAGATA
181	ATCAAAAATT	TACTCTCATT	GCGGATGCCA	GTATTAGGCG	CAGACCGCGA	ATGGAATGCG
241	ATTCATCGAC	TGCGGGATGT	CGGCGTTGAT	ACTATGTATG	GGGTGGCATT	CGGCGAAAAA
301	GGCATTAAATC	CGCTCACCAG	AACCTCGTTT	ATTATAACCG	AAGATCTGAC	ACCAACCATC
361	AGTCTGGAAG	ATTACTGTGC	TGACTGGGCG	ACTAACCAC	CAGATGTTTCG	CGTAAAGCGT
421	ATGCTTATTA	AGCGTGTCGC	GACGATGGTG	CGCGATATGC	ATGCTGCGGG	CATTAACCAC
481	CGCGACTGTT	ATATCTGTCA	TTTCCTGCTA	CACTTGCCTT	TTTCCGGTAA	GGAAGAGGAG
541	TTAAAAATTT	CGGTAATTGA	CCTGCACCGG	GCGCAGCTTC	GCACGCGCGT	TCCACGTCGT
601	TGGCGCGATA	AAGATCTTAT	TGGGCTTTAT	TTTTCTTCGA	TGAATATCGG	CCTGACTCAG
661	CGGGATATCT	GGCGTTTAT	GAAAGTGTAT	TTTGCCGCCC	CGCTTAAAGA	CATTCTCAAG
721	CAGGAACAAG	GACTGCTGTC	GCAAGCAGAA	GAAAAAGCCA	CAAAAATCAG	GGAAAGAACG
781	ATTCGAAAAT	CGTTG				

9/9

FIGURE 9

LOCUS	RFAPR4	265 AA	PROT
FEATURES	From	To/Span	Description
Peptide	1	265	1 to 795 of R4rfaP (translated)
ORIGIN			
1	MVELKEPFAT	LWRGKDPFEE	VKTLOGEVFR ELETTRTLRF EMAGKSYFLK WHRGTTLKEI
61	IKNLLSLRMP	VLGADREWNA	IHRLRDVGVD TMYGVAFGEK GINPLTRTSF IITEDLTPTI
121	SLEDYCADWA	TNPPDVRVKR	MLIKRVATMV RDMHAAGINH RDCYICHFLH HLPFSGKEEE
181	LKISVIDLHR	AQLRTRVPRR	WRDKDLIGLY FSSMNIGLTQ RDIWRFMKVY FAAPLKDILK
241	QEQGLLSQAE	EKATKIRERT	IRKSL

SUBSTITUTE SHEET (RULE 26)

## SEQUENCE LISTING

<110> Whitfield, Chris  
Yethon, Jeremy A.  
Heinrichs, David E.  
University of Guelph

<120> A Novel Gene and Method of Treating a Gram Negative  
Bacterial Infection

<130> 6580-163

<140>

<141>

<150> 60/089,189

<151> 1998-06-12

<150> 60/096,026

<151> 1998-08-10

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 795

<212> DNA

<213> E.coli

<400> 1

```
atggttggaac ttaaagagcc gtttgccacg ttatggcgcg gcaaagatcc ttttgaggaa 60
gttaaaacct tgcaggggtga ggtatttcgt gaactggaaa ctgcgcgtac tctgcgcttt 120
gaaatggcgg gcaaaagcta ttttctcaaa tggcatcgcg gcacgaccct gaaagagata 180
atcaaaaatt tactctcatt gcggatgccg gtattaggcg ctgaccgcga atggaatgcg 240
attcatcgac tgcgggatgt cggcgttgat actatgtatg ggggtggcatt tggcgaaaaa 300
ggcatgaatc cgctgaccag aacttcattt attattaccg aagatctgac accaaccata 360
agtctggaag attactgtgc tgactggcg actaaccctc cagatgttcg cgtaaagcgt 420
atgcttatta agcgtgtcgc gacgatggcg cgcatatgc atgctgcggg cattaaccac 480
cgtgactgtt atatctgtca tttcctgctg cacttgccct tttccggtaa ggaagaggag 540
ttaaaaattt cggtaatga cctgcaccgg gcgcagcttc gcacgcgcgt tccacgtcgt 600
tggcgggata aagatcttat tgggctttat ttttcttcga tgaatatcgg cctgactcag 660
cgggatattt ggcggtttat gaaagtgtat ttgcccgc cgcttaaaga cattctcaag 720
caggaacaag gactgctgtc gcaagcagaa gcaaaagcca caaaaatcag ggaaagaacg 780
attcgaatcg cgttg 795
```

<210> 2

<211> 265

<212> PRT

<213> E.coli

<400> 2

```
Met Val Glu Leu Lys Glu Pro Phe Ala Thr Leu Trp Arg Gly Lys Asp
  1                      5                      10                      15
```

```
Pro Phe Glu Glu Val Lys Thr Leu Gln Gly Glu Val Phe Arg Glu Leu
      20                      25                      30
```

```
Glu Thr Arg Arg Thr Leu Arg Phe Glu Met Ala Gly Lys Ser Tyr Phe
      35                      40                      45
```

```
Leu Lys Trp His Arg Gly Thr Thr Leu Lys Glu Ile Ile Lys Asn Leu
      50                      55                      60
```

2

Leu Ser Leu Arg Met Pro Val Leu Gly Ala Asp Arg Glu Trp Asn Ala  
 65 70 75 80  
 Ile His Arg Leu Arg Asp Val Gly Val Asp Thr Met Tyr Gly Val Ala  
 85 90 95  
 Phe Gly Glu Lys Gly Met Asn Pro Leu Thr Arg Thr Ser Phe Ile Ile  
 100 105 110  
 Thr Glu Asp Leu Thr Pro Thr Ile Ser Leu Glu Asp Tyr Cys Ala Asp  
 115 120 125  
 Trp Ala Thr Asn Pro Pro Asp Val Arg Val Lys Arg Met Leu Ile Lys  
 130 135 140  
 Arg Val Ala Thr Met Val Arg Asp Met His Ala Ala Gly Ile Asn His  
 145 150 155 160  
 Arg Asp Cys Tyr Ile Cys His Phe Leu Leu His Leu Pro Phe Ser Gly  
 165 170 175  
 Lys Glu Glu Glu Leu Lys Ile Ser Val Ile Asp Leu His Arg Ala Gln  
 180 185 190  
 Leu Arg Thr Arg Val Pro Arg Arg Trp Arg Asp Lys Asp Leu Ile Gly  
 195 200 205  
 Leu Tyr Phe Ser Ser Met Asn Ile Gly Leu Thr Gln Arg Asp Ile Trp  
 210 215 220  
 Arg Phe Met Lys Val Tyr Phe Ala Ala Pro Leu Lys Asp Ile Leu Lys  
 225 230 235 240  
 Gln Glu Gln Gly Leu Leu Ser Gln Ala Glu Ala Lys Ala Thr Lys Ile  
 245 250 255  
 Arg Glu Arg Thr Ile Arg Lys Ser Leu  
 260 265

<210> 3  
 <211> 795  
 <212> DNA  
 <213> E.coli

<400> 3  
 atggttgaac ttaaagagcc gtttgccacg ttatggcgcg gcaaagatcc ttttgaggaa 60  
 gttaaaacct tgcagggtga ggtatctcgt gaactggaaa ctgcgcgtac tctgcgcttt 120  
 gaaatggcgg gcaaaagcta ttttctcaaa tggcatcgcg gcacgaccct gaaagagata 180  
 atcaaaaatt tactctcatt gcggatgccg gtattaggcg ctgaccgcga atggaatgcg 240  
 attcatcgac tgcgggatgt cggcggtgat actatgtatg gggtggcatt tggcgaaaaa 300  
 ggcataaatc cgctgaccag aacttcattt attattaccg aagatctgac accaaccata 360  
 agtcttgaag attacagtgc tgactgggcg actaacctc cagatgttcg cgtaaagcgt 420  
 atgcttatta agcgtgtcgc gacgatgggtg cgcgatatgc atgctgcggg cattaaccac 480  
 cgtgactgtt atatctgtca tttcctgctg cacttgcctt tttccggtta ggaagaggag 540  
 ttaaaaattt cggttaattga cctgcaaccg gcgcagcttc gcacgcgcgt tccacgtcgt 600  
 tggcgggata aagatcttat tgggctttat ttttcttcga tgaatatcgg cctgactcag 660  
 cgggatatac ggcggtttat gaaagtgtat tttgccgccc cgcttaaaga cattctcaag 720  
 caggaacaag gactgctgtc gcaagcagaa gcaaaagcca caaaaatcag ggaaagaacg 780  
 attcgaaaat cgttg 795

<210> 4  
 <211> 265  
 <212> PRT  
 <213> E.coli

SUBSTITUTE SHEET (RULE 26)

3

<400> 4  
 Met Val Glu Leu Lys Glu Pro Phe Ala Thr Leu Trp Arg Gly Lys Asp  
 1 5 10 15  
 Pro Phe Glu Glu Val Lys Thr Leu Gln Gly Glu Val Phe Arg Glu Leu  
 20 25 30  
 Glu Thr Arg Arg Thr Leu Arg Phe Glu Met Ala Gly Lys Ser Tyr Phe  
 35 40 45  
 Leu Lys Trp His Arg Gly Thr Thr Leu Lys Glu Ile Ile Lys Asn Leu  
 50 55 60  
 Leu Ser Leu Arg Met Pro Val Leu Gly Ala Asp Arg Glu Trp Asn Ala  
 65 70 75 80  
 Ile His Arg Leu Arg Asp Val Gly Val Asp Thr Met Tyr Gly Val Ala  
 85 90 95  
 Phe Gly Glu Lys Gly Met Asn Pro Leu Thr Arg Thr Ser Phe Ile Ile  
 100 105 110  
 Thr Glu Asp Leu Thr Pro Thr Ile Ser Leu Glu Asp Tyr Ser Ala Asp  
 115 120 125  
 Trp Ala Thr Asn Pro Pro Asp Val Arg Val Lys Arg Met Leu Ile Lys  
 130 135 140  
 Arg Val Ala Thr Met Val Arg Asp Met His Ala Ala Gly Ile Asn His  
 145 150 155 160  
 Arg Asp Cys Tyr Ile Cys His Phe Leu Leu His Leu Pro Phe Ser Gly  
 165 170 175  
 Lys Glu Glu Glu Leu Lys Ile Ser Val Ile Asp Leu His Arg Ala Gln  
 180 185 190  
 Leu Arg Thr Arg Val Pro Arg Arg Trp Arg Asp Lys Asp Leu Ile Gly  
 195 200 205  
 Leu Tyr Phe Ser Ser Met Asn Ile Gly Leu Thr Gln Arg Asp Ile Trp  
 210 215 220  
 Arg Phe Met Lys Val Tyr Phe Ala Ala Pro Leu Lys Asp Ile Leu Lys  
 225 230 235 240  
 Gln Glu Gln Gly Leu Leu Ser Gln Ala Glu Ala Lys Ala Thr Lys Ile  
 245 250 255  
 Arg Glu Arg Thr Ile Arg Lys Ser Leu  
 260 265

<210> 5  
 <211> 795  
 <212> DNA  
 <213> E.coli

<400> 5  
 atggttgaac ttaaagagcc gtttgccacg ttatggcgcg gtaaagatcc ttttgaggaa 60  
 gttaaaacct tgcagggtga ggtatttcgt gaactggaaa ctgcgccgac tctgcgcttt 120  
 gaaatggcgg gcaaaagcta ttttctcaaa tggcatcgcg gcacgaccct gaaagagata 180  
 atcaaaaatt tactctcatt gcggatgccg gtattaggcg cagaccgcga atggaatgcg 240  
 attcatcgac tgcgggatgt cggcgttgat actatgtatg ggggtggcatt cggcgaaaaa 300  
 ggcattaatc cgctcaccag aacctcgttt attataaccg aagatctgac accaaccatc 360  
 agtctggaag attactgtgc tgactgggcg actaaccac cagatgttcg cgtaaagcgt 420

SUBSTITUTE SHEET (RULE 26)

4

```

atgcttatta agcgtgtcgc gacgatggtg cgcgatatgc atgctgcggg cattaaccac 480
cgcgactgtt atatctgtca ttctctgcta cacttgccct tttccggtaa ggaagaggag 540
ttaaaaaatt cggttaattga cctgcaccgg gcgcagcttc gcacgcgcgt tccacgtcgt 600
tgggcgcgata aagatcttat tgggctttat ttttcttcga tgaatatcgg cctgactcag 660
cgggatatct ggcggtttat gaaagtgtat tttgccgccc cgcttaaaga cattctcaag 720
caggaacaag gactgctgtc gcaagcagaa gaaaaagcca caaaaatcag ggaaagaacg 780
attcgaaaat cgttg 795

```

<210> 6  
 <211> 265  
 <212> PRT  
 <213> E.coli

<400> 6  
 Met Val Glu Leu Lys Glu Pro Phe Ala Thr Leu Trp Arg Gly Lys Asp  
 1 5 10 15  
 Pro Phe Glu Glu Val Lys Thr Leu Gln Gly Glu Val Phe Arg Glu Leu  
 20 25 30  
 Glu Thr Arg Arg Thr Leu Arg Phe Glu Met Ala Gly Lys Ser Tyr Phe  
 35 40 45  
 Leu Lys Trp His Arg Gly Thr Thr Leu Lys Glu Ile Ile Lys Asn Leu  
 50 55 60  
 Leu Ser Leu Arg Met Pro Val Leu Gly Ala Asp Arg Glu Trp Asn Ala  
 65 70 75 80  
 Ile His Arg Leu Arg Asp Val Gly Val Asp Thr Met Tyr Gly Val Ala  
 85 90 95  
 Phe Gly Glu Lys Gly Ile Asn Pro Leu Thr Arg Thr Ser Phe Ile Ile  
 100 105 110  
 Thr Glu Asp Leu Thr Pro Thr Ile Ser Leu Glu Asp Tyr Cys Ala Asp  
 115 120 125  
 Trp Ala Thr Asn Pro Pro Asp Val Arg Val Lys Arg Met Leu Ile Lys  
 130 135 140  
 Arg Val Ala Thr Met Val Arg Asp Met His Ala Ala Gly Ile Asn His  
 145 150 155 160  
 Arg Asp Cys Tyr Ile Cys His Phe Leu Leu His Leu Pro Phe Ser Gly  
 165 170 175  
 Lys Glu Glu Glu Leu Lys Ile Ser Val Ile Asp Leu His Arg Ala Gln  
 180 185 190  
 Leu Arg Thr Arg Val Pro Arg Arg Trp Arg Asp Lys Asp Leu Ile Gly  
 195 200 205  
 Leu Tyr Phe Ser Ser Met Asn Ile Gly Leu Thr Gln Arg Asp Ile Trp  
 210 215 220  
 Arg Phe Met Lys Val Tyr Phe Ala Ala Pro Leu Lys Asp Ile Leu Lys  
 225 230 235 240  
 Gln Glu Gln Gly Leu Leu Ser Gln Ala Glu Glu Lys Ala Thr Lys Ile  
 245 250 255  
 Arg Glu Arg Thr Ile Arg Lys Ser Leu  
 260 265

SUBSTITUTE SHEET (RULE 26)

5

<210> 7  
<211> 25  
<212> DNA  
<213> E.coli

<400> 7  
tgtggatcca aatagtgggc actca

25

<210> 8  
<211> 25  
<212> DNA  
<213> E.coli

<400> 8  
gggtgggtcca tatggttgaa cttaa

25

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/54, 9/12, C07K 16/40, A61K 38/17,</b> <b>G01N 33/50 // (C12N 9/12, C12R 1:19)</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/66049</b>  <b>(43) International Publication Date:</b> 23 December 1999 (23.12.99)
<b>(21) International Application Number:</b> PCT/CA99/00545  <b>(22) International Filing Date:</b> 11 June 1999 (11.06.99)  <b>(30) Priority Data:</b> 60/089,189      12 June 1998 (12.06.98)      US 60/096,026      10 August 1998 (10.08.98)      US  <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF GUELPH [CA/CA]; Office of the Vice President of Research, Reynolds Building, Room 214, Guelph, Ontario N1G 2W1 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WHITFIELD, Chris [CA/CA]; 21 Springdale Boulevard, Guelph, Ontario N1H 6X5 (CA). YETHON, Jeremy, A. [CA/CA]; 338 Ironwood Road, Guelph, Ontario N1G 3N8 (CA). HEINRICHS, David, E. [CA/CA]; 6 Delaware Street, Guelph, Ontario N1E 3V3 (CA).  <b>(74) Agent:</b> BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 2 March 2000 (02.03.00)
<b>(54) Title:</b> A NOVEL GENE AND METHOD OF TREATING A GRAM NEGATIVE BACTERIAL INFECTION  <b>(57) Abstract</b>  Described are a novel gene ( <i>waaP</i> ) and a protein (WaaP) which has an enzymatic activity that is involved in heptose modification in the lipopolysaccharide of bacterial membranes. Also described is a method and series of compounds which are active against bacterial pathogens wherein the method comprises the administration of sufficient amount of an inhibitor of WaaP protein activity in gram negative bacteria.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00545

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/54 C12N9/12 C07K16/40 A61K38/17 G01N33/50  
 //(C12N9/12,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CRAIG T PARKER ET AL: "Identification and sequences of the lipopolysaccharide core biosynthetic genes rfaQ, rfaP, and rfaG of Escherichia coli K-12" JOURNAL OF BACTERIOLOGY, vol. 3, no. 174, 1 February 1992 (1992-02-01), page 930 934 XP002072854 ISSN: 0021-9193 cited in the application the whole document	1,3,4
Y		6-11, 16-24
A	---	2,5
	--- -/--	

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

21 December 1999

Date of mailing of the international search report

12.01.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Galli, I

## INTERNATIONAL SEARCH REPORT

Patent Application No  
PCT/CA 99/00545

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HEINRICHS D.E. ET AL.: "The assembly system for the lipopolysaccharide R2 core-type of Escherichia coli is a hybrid of those found in Escherichia coli K-12 and Salmonella enterica" J. BIOL. CHEM., vol. 273, no. 15, 10 April 1998 (1998-04-10), pages 8849-8859, XP002118872	1,3,4
A	the whole document	2,5
X	A G WALSH ET AL: "rfa genes of Pseudomonas aeruginosa" ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, 4 May 1997 (1997-05-04), page 65 XP002072856 ISSN: 0067-2777 -& WO 98 50557 A (MATEWISH M., UNIV. GUELPH) 12 November 1998 (1998-11-12) abstract figure 4 claims 1-25	1,3,4
Y	MAMAT U. ET AL.: "Repression of lipopolysaccharide biosynthesis in Escherichia coli by an antisense RNA of Acetobacter methanolicus phage Acml" MOLECULAR MICROBIOL., vol. 15, no. 6, 1995, pages 1115-1125, XP000857877 the whole document	6-11, 16-24
A	GOLDMAN R. ET AL.: "Antibacterial agents specifically inhibiting lipopolysaccharide synthesis" NATURE, vol. 329, 10 September 1987 (1987-09-10), pages 162-164, XP002126442 the whole document	6-11, 16-24
P,X	DATABASE GENBANK 'Online! Accession No. AF0197545, 3 November 1998 (1998-11-03) HEINRICHS ET AL.: "WaaP protein" XP002118876 -& HEINRICHS D.E. ET AL.: "Molecular basis for structural diversity in the core regions of the polysaccharides of Escherichia coli and Salmonella enterica" MOLECULAR MICROBIOLOGY, vol. 30, no. 2, 1998, pages 221-232, XP002118873 the whole document	1-5

-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 99/00545

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>HEINRICHS D.E. ET AL.: "The assembly system for the outer core portion of R1 and R4 type lipopolysaccharides of E. coli"</p> <p>J. BIOL. CHEM., vol. 273, no. 45, 6 November 1998 (1998-11-06), pages 29497-29505, XP002118874 the whole document</p> <p style="text-align: center;">---</p>	1-5
P,X	<p>YETHON J.A. ET AL.: "Involvement of waaY, waaQ and waaP in the modification of E. coli lipopolysaccharide and their role in the formation of a stable outer membrane."</p> <p>J. BIOL. CHEM., vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26310-26316, XP002118875 the whole document</p> <p style="text-align: center;">-----</p>	1-5

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 99/00545

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 6-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
1-11 16-24
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 99/00545

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 16-24 refer to inhibitors of WaaP, but only claims 20,22,24 give a vague technical characterization. Moreover, these inhibitors are not defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No meaningful search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Claim 9, is inconsistent in the light of claim 10, since it does not relate to a method.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 99/00545

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: (1-5) - completely

An isolated nucleic acid molecule containing a sequence encoding a protein having the activity associated with a WaaP protein, and the corresponding polypeptides.

1.1. Claims: (1-5)

wherein WaaP is derived from E. Coli F470 (seq. ID 1,2)

1.2. Claims: (1-5)

wherein WaaP is derived from E. Coli F653 (seq. ID 3,4)

1.3. Claims: (1-5)

wherein WaaP is derived from E. Coli F2513 (seq. ID 5,6)

2. Claims: (6-11,16-24) - completely

A method for assaying for inhibitors of WaaP activity in gram negative pathogens, comprising the steps of incubating the pathogens with a test substance and assaying for WaaP activity.

An inhibitor of WaaP activity in a gram negative pathogen, and a corresponding composition for use in the attenuation of a virulent gram negative pathogen in an animal. Use in therapeutic applications.

3. Claims: (12-15) - completely

A vaccine for preventing or treating a gram negative bacterial infection comprising an effective amount of a WaaP protein. Use in therapeutic applications.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**